US20170105246A1 - Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols - Google Patents
Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols Download PDFInfo
- Publication number
- US20170105246A1 US20170105246A1 US15/388,881 US201615388881A US2017105246A1 US 20170105246 A1 US20170105246 A1 US 20170105246A1 US 201615388881 A US201615388881 A US 201615388881A US 2017105246 A1 US2017105246 A1 US 2017105246A1
- Authority
- US
- United States
- Prior art keywords
- heating element
- airflow
- substance
- certain embodiments
- airway
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 133
- 238000009833 condensation Methods 0.000 title claims abstract description 104
- 230000005494 condensation Effects 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title abstract description 24
- 239000000126 substance Substances 0.000 claims abstract description 139
- 238000010438 heat treatment Methods 0.000 claims description 110
- 239000011888 foil Substances 0.000 claims description 78
- 229910052751 metal Inorganic materials 0.000 claims description 55
- 239000002184 metal Substances 0.000 claims description 55
- 230000008016 vaporization Effects 0.000 claims description 22
- 239000010935 stainless steel Substances 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 62
- 229940079593 drug Drugs 0.000 abstract description 41
- 239000003814 drug Substances 0.000 abstract description 41
- 238000009826 distribution Methods 0.000 abstract description 16
- 230000002685 pulmonary effect Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 229960002428 fentanyl Drugs 0.000 description 24
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 24
- 238000009834 vaporization Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 238000000151 deposition Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 230000008021 deposition Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- -1 e.g. Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 229960003089 pramipexole Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
- 229960001879 ropinirole Drugs 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- 229960003386 triazolam Drugs 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229940029995 appetite stimulants Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- RFWTZQAOOLFXAY-BZDYCCQFSA-N estradiol enanthate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 RFWTZQAOOLFXAY-BZDYCCQFSA-N 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229960004053 ibutilide Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007761 roller coating Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000002996 urinary tract agent Substances 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 238000001947 vapour-phase growth Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B1/00—Details of electric heating devices
- H05B1/02—Automatic switching arrangements specially adapted to apparatus ; Control of heating devices
- H05B1/0227—Applications
- H05B1/023—Industrial applications
- H05B1/0244—Heating of fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/008—Electronic counters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/0081—Locking means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1075—Preparation of respiratory gases or vapours by influencing the temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B2203/00—Aspects relating to Ohmic resistive heating covered by group H05B3/00
- H05B2203/021—Heaters specially adapted for heating liquids
Definitions
- This disclosure relates to devices capable of entraining a substance into an airflow, to articles and methods employing such devices, and in particular to articles and methods of producing multiple doses of a condensation aerosol of a drug having high purity, high yield, characterized by a particle size distribution suitable for inhalation delivery, and which can be administered to a user during a single inhalation.
- Pulmonary delivery is known as an effective way to administer physiologically active compounds to a patient for the treatment of diseases and disorders.
- Devices developed for pulmonary delivery generate an aerosol of a physiologically active compound that is inhaled by a patient where the compound can be used to treat conditions in a patient's respiratory tract and/or enter the patient's systemic circulation.
- Devices for generating aerosols of physiologically active compounds include nebulizers, pressurized metered-dose inhalers, and the dry powder inhalers. Nebulizers are based on atomization of liquid drug solutions, while pressurized metered-dose inhalers and dry powder inhalers are based on suspension and dispersion of dry powder in an airflow and/or propellant.
- Aerosols for inhalation of physiologically active compounds can also be formed by vaporizing a substance to produce a condensation aerosol comprising the active compounds in an airflow.
- a condensation aerosol is formed when a gas phase substance formed from vaporization condenses or reacts to form particulates (also called particles herein) in the air or a gas. Examples of devices and methods employing vaporization methods to produce condensation aerosols are disclosed in U.S. Pat. Nos. 6,682,716; 6,737,042; 6,716,415; 6,716,416; 6,740,307; 6,740,308; 6,737,043; 6,740,309; and 6,716,417, each of which is incorporated herein by reference.
- an inhalation device be capable of delivering multiple doses of a physiologically active compound and that each dose comprising the active compound be administered to a patient during a single inhalation.
- a dose refers to the amount of a substance released during one activation of an inhalation device.
- a dose can comprise, for example, a therapeutically effective amount of a physiologically active compound.
- treatment regimens can require that each of the multiple doses delivered to a patient comprise a controlled amount of a physiologically active compound, and that the active compound administered exhibit high purity and be free of byproducts, e.g., excipients.
- Optimal delivery of a dose to a patient's respiratory tract, and in particular to a patient's lungs, can also be facilitated by the aerosol having a mass median aerodynamic diameter of less than about 4 ⁇ m.
- practical considerations make it desirable that a substantial amount of each dose contained in the device, form an aerosol, be emitted from the device, and be inhaled by the patient.
- a certain portion of the aerosol can deposit on downstream physical features such as the side walls of the airway defining the airflow, the mouthpiece of the device, or other structures and thereby reduce the amount of active compound emitted by the device and available for administration.
- packaging the multiple doses within a common airway can be attractive for producing low cost and compact products.
- a certain amount of an aerosol particles formed by vaporizing an upstream dose can deposit onto downstream surfaces comprising unvaporized compound.
- the deposition on unvaporized doses reduce the amount of active compound emitted from the device, but in addition, the deposition can change the amount of active compound forming subsequent doses.
- the latter doses can comprise a variable and uncontrolled amount of an active compound.
- the ability to deliver a dose comprising a precise, consistent, and reproducible amount of a physiologically active compound can impact the therapeutic efficacy of the treatment regimens, and in some cases, such a capability can also enable new therapies.
- inhalation devices and methods of producing a condensation aerosol that can repeatedly deliver precise, reproducible and/or controlled amounts of a physiologically active substance.
- Certain embodiments include devices for entraining a substance within an airflow comprising an airway with an inlet, and an outlet; at least one support disposed within the airway; the substance disposed on the at least one support; and a mechanism configured to release the substance from the at least one support; wherein an airflow passing from the inlet to the outlet is directed to the at least one support such that the substance is entrained in the airflow when released from the support.
- Certain embodiments include electrically resistive heating elements comprising a metal foil for vaporizing a substance disposed thereon to produce a condensation aerosol comprising the substance.
- Certain embodiments include devices for delivering a condensation aerosol to a subject comprising a dispensing unit and a separable cartridge.
- the dispensing unit comprises a first housing comprising a receptacle for a separable cartridge; a controller for controlling vaporization of the substance; and a power source.
- the separable cartridge comprises a second housing; an airway contained within the housing having an inlet, and an outlet; a mouthpiece coupled to the outlet; an air bypass hole coupled to the outlet; at least one electrically resistive heating element disposed within the airway; a substance disposed on the at least one heating element; and an actuation mechanism configured to transfer energy from the power source to the at least one heating element; wherein an airflow from the inlet to the outlet of the airway causes the substance to vaporize and condense in the airflow to form a condensation aerosol.
- Certain embodiments include methods of entraining a vaporized substance or aerosol particles into an airflow, methods of producing a condensation aerosol, and methods of administering a substance to a subject using the devices disclosed herein.
- “entrain” or “entraining” means to direct, lift, draw in or along, inject, transport, carry, or suspend a vaporized substance or aerosol particle into an airflow.
- FIG. 1A is a schematic illustration showing deposition of a substance on downstream surfaces.
- FIG. 1B is a schematic illustration showing the use of an airflow through a plurality of holes to entrain a substance into an airflow and thereby minimize deposition of the substance on downstream surfaces according to certain embodiments.
- FIGS. 2A-2F are schematic illustrations showing examples of airflow routing in a device for entraining a condensation aerosol particle into an airflow according to certain embodiments.
- FIG. 3 is an isometric diagram of a separable cartridge for an electric multi-dose condensation aerosol delivery device.
- FIG. 4 shows the airflow rate in the airway for different total airflow rates for a cartridge.
- FIG. 5 is a schematic cross-sectional illustration of a separable cartridge for an electric multi-dose condensation aerosol delivery device showing the routing of the airflow according to certain embodiments.
- FIGS. 6A and 6B show views of a structure separating the first airway and the second airway according to certain embodiments.
- FIG. 7 is a isometric view of an electric multi-dose condensation aerosol delivery device.
- FIG. 8 is a cut-away isometric view of a portion of an electric multi-dose condensation aerosol delivery device.
- FIG. 9 is an isometric view of a dispensing unit for an electric multi-dose condensation aerosol delivery device.
- FIG. 10 is a schematic illustration showing a view of an arched metal foil according to certain embodiments.
- FIGS. 11A-D show an example of the distortion of a flat metal foil, and an arched metal foil before and during resistive heating.
- FIG. 12 is a partial cross-sectional view of a separable cartridge including air routing according to certain embodiments.
- FIG. 13 is a block diagram of an embodiment the electrical functions for an electric multi-dose condensation aerosol delivery device.
- FIG. 14 shows the particle size distribution of a condensation aerosol comprising a substance emitted from an electric multi-dose condensation aerosol delivery device according to certain embodiments.
- FIG. 15 shows the reproducibility of the amount and purity of doses of fentanyl emitted from a new, an opened, and a partially-used electric multi-dose condensation aerosol delivery device according to certain embodiments.
- FIG. 16 shows a temperature profile of a metal foil in an airflow according to certain embodiments.
- FIGS. 17A and 17B show the temperature uniformity of a metal foil in an airflow with fentanyl as the substance according to certain embodiments.
- FIG. 18 shows the amount of substance deposited on downstream heating elements from vaporized substances from preceding heating elements for different airflow velocities with little or no airflow directed upward from underneath the heating elements.
- FIG. 19 shows the amount of substance deposited on downstream heating elements from vaporized doses with a percentage of the total airflow directed upward from underneath the heating elements, where the airflow distribution was controlled by a layer of foam between the first and second airways.
- FIGS. 20A and 20B show a relationship between the temperature of a metal foil and the purity and amount of the dose emitted from an electric multi-dose condensation aerosol delivery device according to certain embodiments.
- Condensation aerosols can be formed when a gaseous substance condenses or reacts to form particulates in air or a gas.
- a gaseous substance can be produced when a solid or liquid substance is thermally sublimed or vaporized.
- Vaporization refers to a phase transition in which a substance changes from a solid or liquid state into a gaseous state.
- Sublimation refers to a phase transition in which a substance passes directly from a solid state to a gaseous state.
- a gaseous substance Upon entering an airflow, a gaseous substance can cool and, at least in part depending on the temperature of the airflow, can condense to form an aerosol particle. Condensation aerosol particles not sufficiently entrained within the airflow have a greater probability of falling out of the airflow to deposit on a downstream surface.
- FIG. 1A shows an airway 10 having an inlet 11 and an outlet 12 .
- a plurality of supports 13 are located on one side of airway 10 .
- Plurality of supports 13 include support 14 and downstream supports 17 .
- a substance can be disposed, for example, on support 14 , and an airflow 15 established in airway 10 such that plurality of supports 13 including support 14 are disposed in airflow 15 .
- the substance disposed on support 14 is released from support 14 by, for example, vaporization, the substance can form condensation aerosol particles 16 in airflow 15 .
- condensation aerosol particles 16 so formed can deposit on downstream supports 17 .
- FIG. 1B shows a schematic illustration of a device for entraining a particulate, and in particular an aerosol-forming gas phase substance, within an airflow.
- FIG. 1B shows a first airway 20 and a second airway 21 separated by a structure 22 .
- Structure 22 comprises a plurality of holes fluidly connecting first airway 20 and second airway 21 .
- a plurality of supports 28 including upstream support 24 , and downstream supports 27 are disposed on the surface of structure 22 within first airway 20 .
- a substance can be disposed, for example, on upstream support 24 .
- a first airflow 25 can be established in first airway 20
- a second airflow 26 can be established in second airway 21 such that second airflow 26 passes from second airway 21 to first airway 20 through the plurality of holes as indicated by the upward pointing arrows 23 .
- second airflow 26 can provide a flow of air directed toward plurality of supports 28 , including upstream support 24 and directed toward airflow 25 .
- the flow of air 23 directed toward airflow 25 can act to lift a substance vaporized from upstream support 24 to form condensation aerosol particles 19 comprising the substance, and entrain the condensation particles within first airflow 25 . Entrainment of condensation particles 19 within first airflow 25 will reduce the likelihood that the condensation particles 19 will become deposited on the downstream surfaces 27 .
- condensation particles near the center of first airflow 25 by entraining the condensation particles near the center of first airflow 25 , more of the condensation particles can be emitted as an aerosol from the outlet 29 of the device and be available, for example, for administration to a subject by inhalation.
- FIG. 2A shows another scheme for routing an airflow through a plurality of holes and across a surface of a structure.
- FIG. 2A shows a device having a first airway 30 , a second airway 31 , and a structure 32 separating first airway 30 and second airway 31 .
- structure 32 is shown as comprising two parts, e.g., as indicated by the thick and thin lines, structure 32 can comprise one part or multiple parts.
- Structure 32 includes a plurality of holes 39 which fluidly connect first airway 30 and second airway 31 .
- First airway 30 and second airway 31 are further defined by housing 34 .
- Housing 34 includes an air intake 35 to allow airflow 36 to enter second airway 31 , and an air outlet 37 to allow airflow 36 to exit the device.
- first airway 30 and second airway 31 are further fluidly connected through holes and/or slots dimensioned to permit a greater, less than, or equal portion 38 of airflow 36 to pass into first airway 30 , compared to the portion of airflow the airflow that passes through plurality of holes 39 .
- the relative amounts of airflow to each airway can be altered to suit the desired purpose. In the same manner as described for FIG.
- FIG. 2B shows a device similar to that of FIG. 2A wherein a second airflow 42 , which is a portion of airflow 36 , enters a third airway 43 . Second airflow 42 can then pass through the plurality of holes 39 to provide an airflow directed toward a plurality of supports 40 and the first airway 30 .
- the condensation particles 41 formed by vaporizing a substance disposed on the supports becomes entrained in airflow 36 , which includes airflows 38 and 42 .
- porous element 44 In another embodiment, as shown in FIG. 2C , a portion of first airflow 36 is directed through a porous element 44 . On passing through porous element 44 , this portion of airflow passes between supports 40 and directs the airflow toward first airway 30 .
- Porous element 44 can be fabricated from any material and have any pore size capable of distributing an appropriate portion of the air entering the device through the plurality of holes forming porous element 44 .
- porous element 44 can be an open cell foam, a mesh, a fibrous material, a glass frit, a ceramic filter, a microporous element, and the like.
- How effectively a substance is entrained within an airflow can at least in part depend on the proportion of rate of airflow across the surface of a support, R 1 to the rate of airflow through the plurality of openings, R 2 .
- the appropriate proportion R 1 :R 2 for effectively entraining a substance within an airflow can depend on a number of factors such as the airflow velocity and the distance of the support from the center of the airflow.
- R 1 :R 2 can range from 80:20 to 20:80 and in other embodiments can range from 60:40 to 40:60.
- the proportion R 1 :R 2 can be established by the relative areas of the holes through which the first an second airflows pass. For example, referring to FIG. 2A , a proportion of 60:40 means that the relative area of hole/slot through which airflow 38 passes is 60 and the relative area of the plurality of holes 39 is 40.
- FIG. 2D shows airflow 36 entering the device.
- One portion of airflow 36 passes through a plurality of holes 39 and across a plurality of supports 40 .
- a second portion of airflow 36 is diverted around the plurality of holes (shown on FIG. 2D as 38 ).
- the airflow portion that goes through the plurality of holes 39 and second airflow portion 38 recombine in first airway 30 and pass through mouthpiece 45 to exit the device.
- FIGS. 2E and 2F Different arrangements of the supports with respect to the airflow through the device are shown in FIGS. 2E and 2F .
- airflow 36 enters first airway 30 .
- Airflow 36 is routed over a plurality of supports 40 and recombines to pass through mouthpiece 45 to exit the device.
- FIG. 2F airflow 36 entering first airway 30 passes over plurality of supports 40 to pass through mouthpiece 45 to exit the device.
- FIGS. 1B, 2A-2F can be applied to devices for administering a condensation aerosol to a subject.
- a subject includes mammals and humans.
- a cartridge for administering multiple doses of a condensation aerosol to a subject which employs airflow through a plurality of holes to facilitate entrainment of a substance released from a support within an airflow is illustrated in FIG. 3 .
- An exploded assembly view of such a cartridge is shown in FIG. 3 as part 50 .
- a cross-sectional view of an assembled cartridge is also illustrated in FIG. 5 .
- FIG. 3 shows an isometric assembly view of a cartridge capable of producing multiple doses of a substance for pulmonary administration.
- the cartridge 50 illustrated in FIG. 3 comprises a first shell 52 and a second shell 54 which can be coupled to form a housing. When assembled, one end of first shell 52 and second shell 54 form a mouthpiece 56 for insertion in a subject's mouth.
- An air bypass hole 58 is located adjacent to mouthpiece 56 in second shell 54 to enable air to enter mouthpiece 56 when the rate of airflow generated by inhalation exceeds the rate of airflow controlled by an air inlet valve 62 entering the cartridge.
- the air inlet valve 62 can assist in minimizing any air flow variation from user to user.
- the rate of airflow in the housing can impact particle size and thus controlling air flow variation allows for more control over the particle size generated.
- the airbypass hole 58 allows for flexibility in that it allows the user to breath at a comfortable rate without upsetting the amount of air flow that moves through the housing and across the surface of the supports. For example, a person typically inhales at a flow rate ranging from 30 L/min to 100 L/min A device, however, may have a flow rate of 6 L/min, which refers to the volume of air per time entering the device, being directed across the surface of the supports and emitted from the device, the excess airflow from the person will enter bypass hole 58 .
- Second shell 54 further comprises an air intake 60 (partially hidden).
- Air intake 60 includes air inlet valve 62 that fits into receptacle 64 of second shell 54 .
- air inlet valve 62 controls the airflow rate of the cartridge and can be any valve that can control the amount of air entering the device during a single inhalation by a user. Examples of appropriate valves include flapper valves (a flexible value that bends in response to a pressure differential), umbrella valves, reed valves, or flapping valves that bend in response to a pressure differential, and the like.
- the purpose of air inlet valve 62 is to control the amount of air entering the cartridge regardless of the total airflow rate during and among inhalations.
- the total airflow rate includes the airflow rate through air intake 60 and air inlet valve 62 , and the airflow rate through air bypass hole 58 .
- FIG. 4 demonstrates that a simple flap valve can be used to control the airflow rate through the cartridge to about 6 L/min for total inhalation ranging from 20 L/min to 90 L/min.
- a cartridge was fitted with a flap valve and the airflow rate through the cartridge for various total airflow rates was measured.
- the airflow rate through the cartridge can be relatively independent of the airflow rate generated by an inhalation.
- flow control can be used to control the particle size and particle size distribution of the condensation aerosol emitted from the device.
- the airflow rate can be one of several parameters to be adjusted to produce a desired average particle size and particle size distribution.
- air control valve 62 can be designed to control the airflow through the cartridge between 4 L/min and 8 L/min.
- an airflow control valve can be activated electronically such that a signal provide by a transducer located within the airway can control the position of the valve, or passively, such as, for example, by a pressure differential between the airway and the exterior of the device.
- the cross-sectional area of the airway can be adjusted to produce a desired average particle size and particle size distribution. In certain embodiments the cross-section area of the airway ranges from 0.5 cm 2 to 3 cm 2 .
- second shell 54 further includes a breath actuation mechanism 67 .
- Breath actuation mechanism 67 is electrically coupled to a remotely located controller (not shown) and can send a signal to the controller that interprets the data and activates the generation of a condensation aerosol when a certain pre-established airflow velocity is sensed.
- Breath actuation mechanism 67 can be, for example, a thermistor, which senses temperature in response to airflow.
- First shell 52 and second shell 54 also include a receptacle 68 for retaining electrical connector 70 .
- there can be a counter 66 which identifies the number of supports that have not been actuated in that they have not been heated yet to vaporize the substance contained thereon.
- a structure 72 separates a first airway and a second airway.
- First airway 74 and second airway 76 are formed by structure 72 and the opposing inner walls of first and second shells 52 , 54 , respectively, as shown in the cross-sectional view of the assembled cartridge illustrated in FIG. 5 .
- structure 72 is a printed circuit board enabling electrical connection between connector 70 and a plurality of electrically resistive heating elements 78 .
- Heating elements 78 are mounted on spacer 80 and soldered to interconnection lands 82 disposed on structure 72 .
- Spacer 80 can be a thermally insulating material such as, for example, a printed circuit board material.
- structure 72 includes a plurality of holes 84 extending over most of the surface of structure 72 . Each of the holes 84 extends through the thickness of structure 72 . Structure 72 also includes a set of slots 86 near the end of structure 72 on which connector 70 is mounted. The number and dimensions of plurality of holes 84 and set of slots 86 determine the relative proportion of air which flows through the plurality of holes 84 and set of slots 86 when a subject inhales on mouthpiece 56 . As shown in FIG. 5 , when a subject inhales on mouthpiece 56 of cartridge 50 , an airflow 88 is generated such that air enters air intake 60 , the flow of air entering the device is controlled by air inlet valve 62 to enter second airway 76 .
- a first portion of airflow passes from second airway 76 through a set of slots 86 into first airway 74 to be inhaled by a subject.
- a second portion of airflow passes through plurality of holes 84 and enters first airway 74 to be inhaled by the subject.
- the airflows passing through the plurality of holes 84 and the set of slots 86 combine to pass through mouthpiece 56 to exit the device.
- FIGS. 6A and 6B A top view showing the positioning of plurality of holes 84 and set of slots 86 with respect to plurality of supports 78 is shown in FIGS. 6A and 6B .
- FIG. 6A shows structure 72 comprising connector 70 , set of slots 86 and plurality of holes 84 .
- Set of slots 86 are shown as rectangular slots. However, set of slots 86 can have any number of openings, shapes, and/or dimensions as appropriate to cause a vaporized substance to become entrained within the airflow so as to form a condensation aerosol that exhibits appropriate properties for inhalation administration.
- Plurality of holes 84 is shown as comprising a regular array of round openings.
- plurality of holes 84 can have any number of openings, shapes, and/or dimensions as appropriate to cause a vaporized substance and condensation aerosol particles to be entrained within the airflow to form a condensation aerosol exhibiting appropriate properties for inhalation administration.
- each row of holes 88 can instead be a narrow slot.
- Plurality of holes 84 can also be placed in a different arrangement over the surface of structure 72 .
- holes 84 can be positioned beneath gaps 90 between adjacent heating elements 78 . Air flowing from holes 84 through gaps 90 can direct a substance released from supports 78 into an airflow. In certain embodiments, at least some of the plurality of holes 84 can be located beneath at least some of the supports 78 .
- a cartridge as described in FIGS. 2-6 can be used in a condensation aerosol delivery device for the administration of a physiologically active substance to a subject.
- a solid view of an exemplary condensation aerosol delivery device 100 according to the disclosure is shown in FIG. 7 .
- An isometric view with the top of the device and the cartridge removed is shown in FIG. 8 , and an exploded isometric view of the condensation aerosol delivery device 100 is shown in FIG. 9 .
- the condensation aerosol delivery device 100 includes cartridge 50 and a dispensing unit 102 .
- cartridge 50 can be a separable unit.
- cartridge 50 can be an integral component of dispensing unit 102 .
- Dispensing unit 102 includes a first shell 104 and a second shell 106 which can be assembled to form the housing of dispensing unit 102 . As shown in FIG. 9 , dispensing unit 102 further includes a battery power source 108 , and a printed circuit board 110 incorporating a microprocessor controller 112 , a display 114 , and a connector 116 for connecting the dispensing unit with the cartridge and which also connects to controller 112 and power source 108 comprising three AAA batteries to cartridge 50 .
- the subject places mouthpiece 56 of condensation aerosol delivery device 100 into his or her mouth.
- the subject then inhales on mouthpiece 56 to generate an airflow as described herein.
- the device is triggered.
- a signal from the airflow sensor is sent to the controller to cause the battery power source to connect to at least one support.
- the supports can be, for example, electrically resistive heating elements. Heat produced by the electrically resistive heating element thermally vaporizes the substance disposed thereon. The vaporized substance condenses in the airflow to form condensation particles and hence, a condensation aerosol.
- the airflow passing from beneath the heating element causes the substance vaporized from the heating element or the condensed aerosol particles to become entrained in the airflow as opposed to depositing on other supports prior to passing through the cartridge.
- the aerosol upon passing through the cartridge is subsequently inhaled by the subject.
- Activation of the condensation aerosol delivery device, generation of the condensation aerosol, and inhalation of the condensation aerosol can occur in a single breath.
- the inhaled condensation aerosol then enters the subject's respiratory tract where the condensation aerosol comprising the active substance can be deposited in the respiratory tract, and in particular the pulmonary alveoli, of the subject.
- a device for generating a condensation aerosol can include at least one support and in certain embodiments, for example, as shown in FIGS. 2-5 and 8 , can include a plurality of supports.
- the supports can provide a surface and/or structure on which a substance to be released into an airflow can be disposed.
- the supports can be located at a side of the airway, for example on the surface of the structure, or can be located toward, near, or in the center of the airway.
- the shape and dimensions of the supports, and the material or materials forming the supports can be chosen to facilitate release of a substance disposed on the supports upon the application of energy, to minimize degradation of the substance during release, to cause rapid heating of the substance disposed thereon and/or to minimize the amount of energy used to release the substance.
- Selection of the appropriate material for forming the support can also, at least in part, be determined by the source of energy used to release the substance from the support.
- the source of energy used to release the substance can be mechanical, acoustic, radiation such as microwave, radio frequency or optical, and/or thermal.
- the support can be non-thermally conductive.
- an optical source can be used to ablate and/or vaporize a substance disposed on a support.
- it can be more efficient or practical to heat a thermally conductive support which transfers thermal energy to the substance disposed thereon to release the substance from the support.
- the support can be a thermally conductive material such as a metal, a metal alloy, a metal composite having more than one layer and/or composition, graphite, or the like.
- the metal can be stainless steel, copper, nickel, aluminum, gold, or silver, and can be plated with one or more of the foregoing materials or other metals.
- the thickness of the plating of a metal layer on the metal can be within the range of between 0.001 ⁇ m to 3 ⁇ m and in other embodiments.
- the support can be a semi-conducting material.
- the condensation aerosol delivery device is designed for portable use with a battery power source
- efficient energy use can be desirable.
- Minimization of the energy used to release a substance from a support can, at least in part, depend on the shape and dimensions of the support, the materials forming the support, and the placement of the support within the airway.
- the support can comprise an electrically resistive material such as a foil.
- the foil can be a stainless steel foil and can include a layer of one or more materials such as a gold layer to facilitate, for example, forming an electrical connection, and/or modifying the electrical properties such as the resistance of a portion of the foil.
- the appropriate dimensions for a foil can depend at least in part, on the desired resistance, the amount of substance disposed on the support, the amount of energy needed to vaporize the substance disposed on the support, and/or on mechanical stability considerations.
- thermal isolation can be accomplished by suspending the support in the airflow above the surface of the structure by means of a spacer whereby the ends of the metal foil can be electrically connected to the power source.
- the metal foil can be arched. During heating, thin foils can have a tendency to distort. This phenomenon is schematically illustrated in FIG. 11 , where a metal foil is shown suspended between two conductors.
- FIG. 11( a ) shows a flat metal foil spanning two conductors.
- the flat metal foil can distort as shown schematically in FIG. 11( b ) .
- such mechanical distortion of the foils can interact with the airflow to increase deposition of the condensation aerosol particles on downstream surfaces.
- FIG. 11( c ) An example of an arched foil is shown in FIG. 11( c ) .
- the arched metal foil shown in FIG. 11( c ) can exhibit a slight upward movement as indicated in FIG. 11( d ) , and following heating returns to approximately the same arched configuration as prior to heating.
- the arch can be formed a number of ways, such as, for example, but not limitation, assembly by placing the metal foil, or plurality of metal foils over an arched mandrel and bonding the ends to a platform.
- the metal foil can be too thin to take a permanent set, but can be held in slight compression to maintain the arch.
- the platform on which the arched metal foil is mounted can be for example, a spacer such as spacer 80 as shown in FIG. 3 , or can be structure 72 separating the first and second airways in embodiments where a spacer is not employed.
- the height of the arch can ranges from 0.5 mm to 2 mm.
- the metal foil can be chosen to facilitate the efficient thermal vaporization of a substance from a metal foil, including, but not limited to, the thickness of the metal foil, the impedance of the metal foil, and the ratio of the surface area to the thermal mass of the metal foil.
- the thickness of the metal foil can be less than 0.01 inches, in certain embodiments, less than 0.001 inches, and in certain embodiments, less than 0.0005 inches.
- the impedance of the metal foil be closely matched to the impedance of the power source.
- the difference between the impedance of the resistive heating element and the impedance of the power source can be less than 50% of the impedance of the power source, in certain embodiments, less than 10% of the impedance of the power source, and in certain embodiments, less than 2% of the impedance of the power source.
- the ratio of the surface area of the heating element to the thermal mass of the resistive heating element can be greater than 10 cm 2 /J/° C., in certain embodiments, greater than 100 cm 2 /J/° C., and in certain embodiments, greater than 500 cm 2 /J/° C.
- the support, and in particular, a metal foil can be heated to a temperature of at least 250° C. in less than 500 msec, in certain embodiments, to a temperature of at least 250° C. in less than 250 msec, and in certain embodiments, to a temperature of at least 250° C. in less than 100 msec.
- the thickness of the layer of substance can range from 0.01 ⁇ m to 50 ⁇ m, in certain embodiments, can range from 0.01 ⁇ m to 20 ⁇ m, and in certain embodiments, can range from 0.01 ⁇ m to 10 ⁇ m.
- the amount of energy to thermally vaporize a substance can be minimized by, for example, using an electrically resistive heating element comprising a thin metal foil, closely matching the impedance of the electrically resistive heating element to the impedance of the power source, maximizing the ratio of the surface area of the resistive heating element to the thermal mass of the resistive heating element, and using a thin film of substance disposed on the heating element.
- the amount of energy to vaporize a substance from a support can be less than 250 joules, in certain embodiments, less than 50 joules, and in certain embodiments, less than 10 joules.
- the amount of energy to vaporize one mg of substance from a support can be less than 250 joules, in certain embodiments, less than 50 joules, and in certain embodiments, less than 10 joules.
- a cartridge or drug delivery device can comprise from 1 to 200 supports, in certain embodiments, from 1 to 50 supports, and in certain embodiments, from 1 to 25 supports, and in certain embodiments, from 1 to 10 supports.
- the cartridge can be separable from the condensation aerosol delivery device.
- a subject can use the delivery device, for example, to administer more than one physiologically active substance, or more than one dose of the same physiologically active substance by replacing one cartridge with another. Also, when all the doses in a particular cartridge are exhausted, the user can obtain and insert a new cartridge into the delivery device.
- a drug refers to a substance recognized in an official pharmacopoeia or formulary, and/or a substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease where disease refers to any disease, disorder, condition, symptom or indication.
- the substance disposed on at least one support can comprise a therapeutically effective amount of a drug.
- a therapeutically effective amount or dose of a drug can be disposed on a single support, on each of multiple supports, or on more than one support.
- the same amount of physiologically active compound can be disposed on each support.
- different amounts of a physiologically active compound can be disposed on each of the plurality of supports, or a certain amount of active compound can be disposed on several supports, and a different amount of active compound on several other supports. Having different amounts of a drug on different supports can be useful in effecting treatment regimens where administering a variable amount of drug during a period of time is useful.
- a second compound comprising an agonist can be disposed on one or more other supports.
- “Abusable substance” refers to a substance that can be improperly used, for example, by administering more than a prescribed or intended dosage, or by altering the route of administration from the intended route.
- an opioid analgesic can be abused by using the opioid analgesic to elicit a euphoric effect, rather than therapeutically for the treatment of pain.
- Abusable substances include substances regulated by a regulatory agency focused on preventing drug abuse, such as, for example, the United States Drug Enforcement Agency (DEA).
- DEA United States Drug Enforcement Agency
- an abusable substance can be a substance listed on DEA schedule II, III, IV, or V.
- the second compound is a chemical compound that can act to reduce or to counteract the physiological activity and/or pharmacological effects of another chemical substance. Having both an abusable substance and a second compound capable of counteracting the effects of the abusable substance in the same device will complicate the ability of an abuser to selectively remove the abusable substance from heating elements. Proper use of the device would only allow the abusable substance to be activated in prescribed doses.
- a substance to be released can be disposed on at least one surface of a support.
- the substance can be disposed on the surface facing the center of the first airway and/or toward the part of the airflow where the velocity is highest.
- the substance can be applied to a surface of a support by any appropriate method and can depend at least in part on the physical properties of the substance and the final thickness of the layer to be applied.
- methods of applying a substance to a support include, but are not limited to, brushing, dip coating, spray coating, screen printing, roller coating, inkjet printing, vapor-phase deposition, spin coating, and the like.
- the substance can be prepared as a solution comprising at least one solvent and applied to a support.
- a solvent can comprise a volatile solvent such as acetone, or isopropanol.
- the substance can be applied to a support as a melt.
- a substance can be applied to a film having a release coating and transferred to a support.
- thickening agents can be admixed with the substance to produce a viscous composition comprising the substance that can be applied to a support by any appropriate method, including those described herein.
- a layer of substance can be formed during a single application or can be formed during repeated applications to increase the final thickness of the layer. In other embodiments, the substance can be applied on more than one surface of the support.
- more than one active compound can be disposed on one or more of the plurality of supports.
- a first active compound can be disposed on certain supports, and a second active compound can be disposed on other supports, and in certain embodiments, a composition comprising a first active compound and a second active compound can be disposed on one or more supports.
- a dose can correspond to the amount of active compound released from a single support, or the amount of active compound released from more than one support.
- a dose or dosage as used herein refers to the amount of substance released during a single activation of a condensation aerosol delivery device.
- a dose can comprise a therapeutically amount of a physiologically active compound, meaning that the dose provides effective treatment of a condition and/or disease in a patient.
- the therapeutically effective amount of a physiologically active compound can vary from compound to compound, from subject to subject, and can depend upon factors such as the condition of the subject.
- a substance disposed on at least one support can comprise a therapeutically effective amount of at least one physiologically active compound or drug.
- a therapeutically effective amount refers to an amount sufficient to effect treatment when administered to a patient or user in need of treatment.
- Treating or treatment of any disease, condition, or disorder refers to arresting or ameliorating a disease, condition or disorder, reducing the risk of acquiring a disease, condition or disorder, reducing the development of a disease, condition or disorder or at least one of the clinical symptoms of the disease, condition or disorder, or reducing the risk of developing a disease, condition or disorder or at least one of the clinical symptoms of a disease or disorder.
- Treating or treatment also refers to inhibiting the disease, condition or disorder, either physically, e.g.
- treating or treatment refers to delaying the onset of the disease, condition or disorder or at least symptoms thereof in a patient which may be exposed to or predisposed to a disease, condition or disorder even though that patient does not yet experience or display symptoms of the disease, condition or disorder.
- the amount of substance disposed on a support can be less than 100 micrograms, in certain embodiments, less than 250 micrograms, in certain embodiments, less than 500 micrograms, and in certain embodiments, less than 1,000 micrograms.
- the amount of substance that is vaporized off the surface is important. Consistency of delivery of the compound is also critical. In certain embodiments, at least 80% of the amount of material disposed on each support passes through the outlet of the device for deliver to the subject, in other embodiments, at least 90% passes through the outlet, and in other embodiments, at least 98% passes through the outlet.
- a substance can comprise a pharmaceutical compound.
- the substance can comprise a therapeutic compound or a non-therapeutic compound.
- a non-therapeutic compound refers to a compound that can be used for recreational, experimental, or pre-clinical purposes.
- Classes of drugs that can be used include, but are not limited to, anesthetics, anticonvulsants, antidepressants, antidiabetic agents, antidotes, antiemetics, antihistamines, anti-infective agents, antineoplastics, antiparkinsonian drugs, antirheumatic agents, antipsychotics, anxiolytics, appetite stimulants and suppressants, blood modifiers, cardiovascular agents, central nervous system stimulants, drugs for Alzheimer's disease management, drugs for cystic fibrosis management, diagnostics, dietary supplements, drugs for erectile dysfunction, gastrointestinal agents, hormones, drugs for the treatment of alcoholism, drugs for the treatment of addiction, immunosuppressives, mast cell stabilizers, migraine preparations, motion sickness products, drugs for multiple sclerosis management, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics and stimulants, ophthalmic preparations, osteoporosis preparations, prostaglandins, respiratory agents, sedatives and
- Examples of pharmaceutical compounds include fluticasone propionate, clonidine, triazolam, albuterol, ciclesonide, fentanyl, terbutaline, flumazenil, triamcinolone acetonide, flunisolide, ropinirole, alprazolam, buprenorphine, hyoscyamine, atropine, pramipexole, bumetanide, flunitrazepam, oxymorphone, colchicine, apomorphine HCl, granisetron, pergolide, nicotine, loperamide, azatadine, naratriptan, clemastine, benztropine, ibutilide, butorphanol, fluphenazine, estradiol-17-heptanoate, zolmitriptan, metaproterenol, scopolamine, diazepam, tolterodine, estazolam, haloperidol, carbinoxamine,
- the compound is chosen from alprazolam, buprenorphine, clonindine, fentanyl, midazolam, pramipexole, ropinirole, and triazolam. In certain embodiments, the compound is chosen from a compound for the treatment of pain. In certain embodiments, the compound for the treatment of pain is fentanyl.
- a drug can further comprise substances to enhance, modulate and/or control release, aerosol formation, intrapulmonary delivery, therapeutic efficacy, therapeutic potency, stability, and the like.
- a drug can be co-administered with one or more active agents to increase the absorption and/or diffusion of the first drug through the pulmonary alveoli, or to inhibit degradation of the drug in the systemic circulation.
- a drug can be co-administered with active agents having pharmacological effects that enhance the therapeutic efficacy of the drug.
- a drug can comprise compounds that can be used in the treatment of one or more diseases, conditions, or disorders.
- a drug can comprise more than one compound for treating one disease, condition, or disorder, or for treating more than one disease, condition, or disorder.
- the substance can comprise one or more pharmaceutically acceptable carriers, adjuvants, and/or excipients.
- Pharmaceutically acceptable refers to approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
- substances useful in embodiments of the disclosure can exhibit a heat of vaporization less than about 150 kJoules/mol.
- thermal degradation can be minimized by rapidly heating the substance to a temperature sufficient to vaporize and/or sublime the active substance.
- the support or heating element can be heated to a temperature of at least 250° C. in less than 500 msec, in certain embodiments, to a temperature of at least 250° C. in less than 250 msec, and in certain embodiments, to a temperature of at least 250° C. in less than 100 msec.
- rapid vaporization of a layer of substance can occur with minimal thermal decomposition of the substance, to produce a condensation aerosol exhibiting high purity of the substance.
- less than 10% of the substance is decomposed during thermal vaporization resulting in a condensation aerosol with at least 90% purity and in certain embodiments, less than 5% of the substance is decomposed during thermal vaporization resulting in a condensation aerosol with at least 95% purity, and in other embodiments, less than 2% of the substance is decomposed during thermal vaporization resulting in a condensation aerosol with at least 98% purity.
- the size of the particulates of the compound comprising the aerosol can be within a range appropriate for intrapulmonary delivery.
- an aerosol having a mass median aerodynamic diameter (“MMAD”) ranging from 1 ⁇ m to 3 ⁇ m, and ranging from 0.01 ⁇ m to 0.10 ⁇ m are recognized as optimal for intrapulmonary delivery of pharmaceutical compounds.
- Aerosols characterized by a MMAD ranging from 1 ⁇ m to 3 ⁇ m can deposit on alveoli walls through gravitational settling and can be absorbed into the systemic circulation, while aerosols characterized by a MMAD ranging from about 0.01 ⁇ m to 0.10 ⁇ m can also be deposited on the alveoli walls through diffusion.
- Aerosols characterized by a MMAD ranging from 0.15 ⁇ m to 1 ⁇ m are generally exhaled.
- aerosols produced using devices and methods of producing an aerosol can having a MMAD ranging from 0.01 ⁇ m to 5 ⁇ m, in certain embodiments, a MMAD ranging from 0.05 ⁇ m to 3 ⁇ m, in certain embodiments, a MMAD ranging from 1 ⁇ m to 3 ⁇ m and in certain embodiments, a MMAD ranging from 0.01 ⁇ m to 0.1 ⁇ m.
- aerosols suitable for intrapulmonary delivery of pharmaceutical compounds can further be characterized by the geometric standard deviation of the log-normal particle size distribution.
- aerosols produced using the devices and methods of producing an aerosol comprise a geometric standard deviation of the log-normal particle size distribution of less than 3, in certain embodiments, less than 2.5, and in certain embodiments, less than 2.
- a cartridge can include a part disposed in the mouthpiece to control the airflow exiting the device.
- a partial section view of the cartridge cross-section of FIG. 5 is shown in FIG. 12 .
- FIG. 12 shows the front section of cartridge 50 , further including an air routing part 200 disposed within the mouthpiece 56 .
- the airflow 88 entering air intake 60 , and air inlet valve 62 passes through the internal airways to entrain a condensation aerosol particles, and passes through the orifice defined by air routing part 200 to be emitted from the device.
- Bypass airflow 202 enters bypass opening 58 and is diverted around the outside of air routing part 200 .
- the front 204 of air routing part 200 extends to near the tip 206 of mouthpiece 56 .
- the use of air routing part 200 can be useful in maintaining smooth airflow through the device and facilitating control of the condensation aerosol particle size.
- An embodiment of a condensation aerosol delivery device is the portable electric multi-dose drug delivery systems discussed herein, and illustrated in FIGS. 7 to 9 .
- the electric multi-dose drug delivery system is designed to produce and deliver a therapeutic condensation aerosol into the respiratory tract, and in particular to the pulmonary pathway, of a subject.
- the condensation aerosol delivery device includes two subsystems, referred to as the cartridge and the dispensing unit. Both the cartridge and the dispensing unit incorporate several electronic features which facilitate the portability, safety, versatility, and convenience of the delivery device.
- the cartridge includes the therapeutic drug in individual doses, and electronics to sense airflow generated by the subject's inhalation.
- the dispensing unit includes a battery power source, and a microcontroller that controls the drug vaporization process, and can include a number of communication functions.
- Such communication functions include, but are not limited to, cartridge identification, dose identification, abuse prevention functions, use monitoring, and dose control.
- FIG. 13 shows a cartridge 130 comprising an EEPROM 132 , a breath sensor 134 , and twenty-five drug coated metal foils 136 .
- EEPROM 132 can include, for example, an identifying serial number for the cartridge, a manufacturing date, and/or additional identification and control information, and monitors the number of doses remaining in the cartridge.
- EEPROM 132 is electrically connected to microcontroller 152 contained in the dispensing unit 150 .
- Microcontroller 152 can read or write to EEPROM 132 to update and record the data stored therein.
- EEPROM 132 need not require power to maintain the data.
- Breath actuation sensor 134 includes circuitry for detection of airflow, and is electrically connected to microcontroller 152 .
- the circuitry can comprise two temperature sensing devices such as thermistors, one of which is heated. Air flowing across the heated sensor 134 is transduced as a change in voltage, which is monitored by microcontroller 152 .
- microcontroller 152 connects power source 154 to at least one of resistive metal foils 136 to effect vaporization of the drug disposed thereon.
- Plurality of drug coated foils 136 are electrically connected to a switch matrix 156 which is controlled by microcontroller 152 .
- plurality of drug coated foils 136 can be selectively heated by passing a current through the foils to vaporize the drug coating to form a condensation aerosol in airflow 138 .
- dispensing unit 150 includes microcontroller 152 , power source 154 , switch matrix 156 , a hardware safety lock-out mechanism 158 , a user-activated switch 160 , and a liquid crystal display user interface 162 .
- Microcontroller 152 incorporates embedded software and controls operation of the condensation aerosol delivery device. When not operating, microcontroller 152 is maintained in a sleep mode to conserve power consumption. Upon momentary depression of user activation switch 160 , microcontroller 152 becomes operational. In certain embodiments, microcontroller 152 can also be activated by inserting a cartridge into the delivery device.
- Microcontroller 152 can then check for the presence of cartridge 130 , and if present, microcontroller 152 reads EEPROM 132 to determine whether the serial number of cartridge 130 matches the serial number stored in the controller, and calculates the number of unused doses contained on drug coated foils 136 remaining in cartridge 130 .
- a purpose of matching the cartridge and dispensing unit serial number can be to personalize individual cartridges 130 and dispensing unit 150 to an individual patient. Personalization can be programmed using the embedded software by a health care provider to facilitate and personalize a patient's treatment regimen, and to reduce the potential for abuse by preventing a particular cartridge from being used in a dispensing unit having a different serial number.
- microcontroller 152 Upon verification of the parameters, microcontroller 152 updates display 162 with, for example, the number of doses remaining in cartridge 130 , and waits for an activation signal from breath sensor 134 .
- microcontroller 152 connects power source 154 , through switch matrix 156 , to one or more of drug coated foils 136 to release the drug to form a condensation aerosol comprising the drug in airflow 138 of cartridge 130 that is inhaled by the patient.
- Microcontroller 152 is electrically connected to switch matrix 156 , and can connect one or more of drug-coated foils 136 to power source 154 at a given time.
- microcontroller 152 can connect one or more drug coated foils 136 to power source 154 sequentially, randomly, or in a predetermined order. Following actuation to deliver a dose to the patient, microcontroller 152 can enter a lockout period in which a subsequent dose cannot be released until the lockout period expires. Microcontroller 152 can enter a sleep mode to conserve power until manually activated by depressing user activation switch 160 , inserting a cartridge in the device, and/or removing a cartridge.
- Display 162 is an electronic display which can inform a user of the current state of the device, e.g., whether the device is in the sleep or activated mode, and the number of unused doses remaining in the cartridge.
- User activated switch 160 is a momentary push button switch that when depressed activates the system from the sleep mode.
- Power source 154 comprises three alkaline primary cells that are used to power the system including providing the power necessary to vaporize the drug disposed on metal foils 136 .
- Switch matrix 156 can be an array of MOSFET switches under control of the microcontroller that couple power from power source 154 to the appropriate drug coated foils 136 .
- Hardware safety lockout 158 is a redundant, software-independent system that can prevent more than one dose from being delivered at a time and/or prevent a second dose from being delivered before the end of the lockout period. Hardware safety lockout 158 provides a redundant safety mechanism in the event of software malfunction.
- the device is such that the total airflow passing through the outlet ranges from 10 liters/min to 100 liters/min. In other embodiments, the total airflow passing though the outlet ranges from 20 liters/min to 90 liters/min.
- the airflow rate through the inlet is less than 100 L/min. In other embodiments, the airflow rate through the inlet is less than 50 liters/min. In yet other embodiments, the airflow rate through the inlet is less than 25 liters/min; and in still other embodiments, the airflow rate through the inlet is less than 10 liters/min.
- a condensation aerosol delivery device and in particular an electric condensation aerosol delivery device capable of delivering multiple doses of a physiologically active substance to a patient with each dose being delivered during a single inhalation. It will be appreciated that at least some of the parameters are interactive, and that the multiple parameters can be adjusted by routine optimization procedures to generate a condensation aerosol comprising a dose of a particular physiologically active substance.
- such parameters include, but are not limited to the properties of a particular substance, e.g., heat of vaporization, the quantity of substance comprising a dose, the thickness of the layer disposed on the support, the thickness of the heating element, the ratio of the surface area of the heating element to the thermal mass of the resistive heating element, and the airflow.
- a particular substance e.g., heat of vaporization
- the quantity of substance comprising a dose the thickness of the layer disposed on the support
- the thickness of the heating element the ratio of the surface area of the heating element to the thermal mass of the resistive heating element, and the airflow.
- Embodiments of the present disclosure can be further defined by reference to the following examples, which describe in detail certain embodiments of the present disclosure. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the present disclosure.
- Electric multiple dose condensation aerosol delivery devices as shown in FIGS. 2-5 were fabricated.
- the two halves forming the housing of the cartridge were molded from either acrylonitrile-butadiene-styrene or polycarbonate.
- the structure separating the first and second airways was fabricated from 0.032-inch thick FR4 printed circuit board material. When assembled, the circuit board and the walls of the cartridge define a 3.5 inch long first airway having a cross-sectional area of 1.5 cm 2 , and a 3.0 inch long second airway having a cross-sectional area of 1.5 cm 2 .
- the total resistance through the cartridge was 0.07 sqrt(cm-H 2 O)/L/min at a total airflow rate of 20 L/min and 0.09 sqrt(cm-H 2 O)/L/min at 90 L/min.
- the flow valve was designed to control the flow between 4 L/min and 8 L/min for a total flow rate ranging from 20 L/min to 90 L/min (see FIG. 4 ).
- Circuit boards used to separate the first and second airways were fabricated having different arrangements and dimensions of holes.
- the plurality of holes beneath the metal foils comprised an array of 100 round holes situated beneath the gaps between adjacent metal foils.
- the device incorporated 25 supports.
- the supports were fabricated from 0.0005 inch thick stainless steel foils having a surface area of 0.2 cm 2 and mounted in an arched configuration to minimize distortion during heating.
- Fifty ⁇ g of fentanyl was deposited on the surface of each foil by spray coating from a solution comprising either isopropyl alcohol, acetone, or acetonitrile.
- the 50 ⁇ g layer of fentanyl was 3 ⁇ m thick.
- the resistance of the metal foils on which the fentanyl was deposited was 0.4 ⁇ , the ratio of the surface area of the metal foil to the thermal mass of the heating foil was 47 cm 2 /J/C.
- Either three AAA batteries or a Hewlett Packard 6002A DC power supply were used, depending on the experiment conducted, to provided 1.7 joules of energy to the heating element to vaporize the 50 ⁇ g of fentanyl.
- Aerosol particles can impact the therapeutic efficacy of a pharmaceutical administered by inhalation.
- aerosols having a particle size ranging from 0.01 ⁇ m to 3 ⁇ m are considered optimal for pulmonary delivery.
- Aerosol particle size can be characterized by the mass median aerodynamic diameter (MMAD) of the aerosol.
- MMAD refers to the median of the distribution of particle sizes forming the aerosol.
- Aerosol particle size distributions for condensation aerosols formed using the condensation aerosol delivery device described in Example 1 are presented in FIG. 14 .
- Each foil of a 25-foil cartridge contained 50 ⁇ g of fentanyl as a 3 ⁇ m thick layer.
- a single foil was heated to a peak temperature of 400° C. within 350 msec in a 6 L/min airflow.
- the particle size distribution of the aerosol emitted from the device was measured by the Anderson Impaction method using an eight stage Cascade Impactor Series 20-800 Mark II (Anderson, Copley Scientific, Nottingham, UK).
- the particle size distribution for two replicates from each of front foils (1-5), middle foils (10-15) and back foils (20-25) (closest to the mouthpiece) are presented in FIG. 14 .
- the particle size distribution of the aerosol from each foil is consistent, exhibiting a range of particle size from about 5.8 ⁇ m to about 0 ⁇ m with a MMAD of 1.8 ⁇ m, and a geometric standard deviation (GSD) of 1.7 ⁇ m.
- Example 1 The airflow in a condensation aerosol delivery device as described in Example 1 was adjusted and the particle size of five emitted doses measured using the Anderson impaction method.
- the airflow volume was increased from 4 L/min to 8 L/min to increasing the airflow velocity from 1 m/sec to 2 m/sec.
- a bypass air routing part was inserted into the mouthpiece section of the cartridge (to get the total airflow up to 28.3 L/min for the Andersen impactor to function properly) such that the bypass air and the airflow containing the condensation aerosol joined just prior to entering the impactor.
- test 3 bypass air was introduced into the outgoing airflow immediately after passing over the heating elements. The results are presented in Table 1.
- the stability of fentanyl in multi-dose condensation aerosol delivery devices was determined by measuring the amount and purity of fentanyl in an emitted dose for a newly manufactured cartridge (diagonal lines), an unused cartridge that was stored at room temperature for 7 days (cross-hatch), and a cartridge that was used to emit 10 doses and then stored at room temperature for 7 days (solid). The results are presented in FIG. 15 .
- Three AAA batteries provided 1.7 joules of energy to a 0.0005 inch thick stainless steel foil on which 50 ⁇ g of fentanyl was deposited.
- the airflow velocity was 1 m/sec corresponding to an airflow rate of 4 L/min.
- the temperature of the foil increased to a temperature of about 200° C. within 50 m/sec, a maximum temperature of 400° C. within 284 m/sec, and returned to room temperature within 1.5 sec after reaching maximum temperature.
- the temperature uniformity of a foil having a thin layer of 50 ⁇ g of fentanyl was measured during heating. The results are shown in FIGS. 17A and 17B .
- FIGS. 18 and 19 The effects of the airflow in a cartridge on the deposition of the aerosol particles on downstream surfaces is demonstrated in FIGS. 18 and 19 .
- the results presented in FIG. 18 were obtained using a cartridge as described in Example 1 with the exception that there was no circuit board separating the first and second airways and flow was controlled by flow meters instead of a flow valve.
- the heating elements were supported at the edges only and there was no flow control between the first and second airways; the amount of air entering the first and second airways was controlled by flow meters at the inlet to each airway.
- the first and second airways were separated by a piece of tape to test aerosol particle deposition when all the airflow passed over the top of the heating elements.
- the tape was removed and the flow meters were set such that 90% of the inlet airflow entered through the first airway and 10% entered through the second airway.
- the air that entered through the second airway had to flow through the gaps between the heating elements to reach the airway outlet.
- tape under 16-25 case a piece of tape was placed below heating elements 16-25 and again the flow meters were set such that 90% of the inlet airflow entered through the first airway and 10% entered through the second airway.
- the tape was intended to increase the amount of air flowing up past heating elements 1-15.
- heating elements 3, 9, 16, and 22 contained a 3 ⁇ m thick layer of 50 ⁇ g of fentanyl from which fentanyl was vaporized, with the downstream elements fired before the upstream elements so that any deposited aerosol particles would not be revaporized. As shown in FIG. 18 , for each of these conditions up to about 5 ⁇ g of fentanyl was deposited on each downstream heating element.
- FIG. 19 shows the results from three tests conducted using the same airway as described above for the results in FIG. 18 .
- the first and second airways were separated by a thin piece of foam placed directly below the heating elements and the flow meters were set such that 50% of the inlet airflow entered through the first airway and 50% entered through the second airway.
- the foam created a pressure drop between the first and second airway, evenly distributing the flow from the second airway past each heating element and into the center of the first airway.
- 50 ⁇ g of fentanyl were vaporized from each of the 25 heating elements (in contrast to the experiments from FIG. 18 where fentanyl was only vaporized from 4 heating elements) from downstream heating element 25 to upstream heating element 1, and essentially no fentanyl was deposited on the downstream heating elements.
- FIGS. 20A and 20B The purity and yield of emitted doses for devices as described in Example 1, except that the surface area of each support was 0.25 cm 2 , are presented in FIGS. 20A and 20B .
- FIG. 20A shows that the purity of a 2.4 ⁇ m thick, 60 ⁇ g dose of fentanyl emitted from the device is greater than 98% when the peak temperature of the heating element is at least 375° C.
- FIG. 20B at least 96% of the 2.4 ⁇ m thick, 60 ⁇ g dose of fentanyl disposed on a heating element was emitted from the device when heated to a temperature of at least 375° C.
- the condensation aerosols comprising fentanyl were characterized by a MMAD of 2.0 ⁇ m and a GSD of 1.8 ⁇ m.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 13/717,630, filed Dec. 17, 2012, entitled “Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols”, which is a divisional of U.S. patent application Ser. No. 12/474,680, filed May 29, 2009, entitled “Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols”, which is a divisional of U.S. patent application Ser. No. 10/861,554, filed Jun. 3, 2004, entitled “Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols”. Each of these applications is incorporated herein by reference in its entirety. Any disclaimer that may have occurred during the prosecution of the above-referenced applications is hereby expressly rescinded, and reconsideration of all relevant art is respectfully requested.
- This disclosure relates to devices capable of entraining a substance into an airflow, to articles and methods employing such devices, and in particular to articles and methods of producing multiple doses of a condensation aerosol of a drug having high purity, high yield, characterized by a particle size distribution suitable for inhalation delivery, and which can be administered to a user during a single inhalation.
- Pulmonary delivery is known as an effective way to administer physiologically active compounds to a patient for the treatment of diseases and disorders. Devices developed for pulmonary delivery generate an aerosol of a physiologically active compound that is inhaled by a patient where the compound can be used to treat conditions in a patient's respiratory tract and/or enter the patient's systemic circulation. Devices for generating aerosols of physiologically active compounds include nebulizers, pressurized metered-dose inhalers, and the dry powder inhalers. Nebulizers are based on atomization of liquid drug solutions, while pressurized metered-dose inhalers and dry powder inhalers are based on suspension and dispersion of dry powder in an airflow and/or propellant.
- Aerosols for inhalation of physiologically active compounds can also be formed by vaporizing a substance to produce a condensation aerosol comprising the active compounds in an airflow. A condensation aerosol is formed when a gas phase substance formed from vaporization condenses or reacts to form particulates (also called particles herein) in the air or a gas. Examples of devices and methods employing vaporization methods to produce condensation aerosols are disclosed in U.S. Pat. Nos. 6,682,716; 6,737,042; 6,716,415; 6,716,416; 6,740,307; 6,740,308; 6,737,043; 6,740,309; and 6,716,417, each of which is incorporated herein by reference.
- It can be desirable that an inhalation device be capable of delivering multiple doses of a physiologically active compound and that each dose comprising the active compound be administered to a patient during a single inhalation. A dose refers to the amount of a substance released during one activation of an inhalation device. A dose can comprise, for example, a therapeutically effective amount of a physiologically active compound. Furthermore, treatment regimens can require that each of the multiple doses delivered to a patient comprise a controlled amount of a physiologically active compound, and that the active compound administered exhibit high purity and be free of byproducts, e.g., excipients. Optimal delivery of a dose to a patient's respiratory tract, and in particular to a patient's lungs, can also be facilitated by the aerosol having a mass median aerodynamic diameter of less than about 4 μm. Furthermore, practical considerations make it desirable that a substantial amount of each dose contained in the device, form an aerosol, be emitted from the device, and be inhaled by the patient.
- When a condensation aerosol is formed in an airflow, a certain portion of the aerosol can deposit on downstream physical features such as the side walls of the airway defining the airflow, the mouthpiece of the device, or other structures and thereby reduce the amount of active compound emitted by the device and available for administration. In multiple dose devices, packaging the multiple doses within a common airway can be attractive for producing low cost and compact products. However, in multiple dose devices, where the multiple doses are disposed on surfaces within an airflow, a certain amount of an aerosol particles formed by vaporizing an upstream dose, can deposit onto downstream surfaces comprising unvaporized compound. Not only can the deposition on unvaporized doses reduce the amount of active compound emitted from the device, but in addition, the deposition can change the amount of active compound forming subsequent doses. Thus, particularly where a device includes a large number of multiple doses, the latter doses can comprise a variable and uncontrolled amount of an active compound.
- For many treatment regimens, the ability to deliver a dose comprising a precise, consistent, and reproducible amount of a physiologically active compound can impact the therapeutic efficacy of the treatment regimens, and in some cases, such a capability can also enable new therapies. Thus, there is a need for inhalation devices and methods of producing a condensation aerosol that can repeatedly deliver precise, reproducible and/or controlled amounts of a physiologically active substance.
- Certain embodiments include devices for entraining a substance within an airflow comprising an airway with an inlet, and an outlet; at least one support disposed within the airway; the substance disposed on the at least one support; and a mechanism configured to release the substance from the at least one support; wherein an airflow passing from the inlet to the outlet is directed to the at least one support such that the substance is entrained in the airflow when released from the support.
- Certain embodiments include electrically resistive heating elements comprising a metal foil for vaporizing a substance disposed thereon to produce a condensation aerosol comprising the substance.
- Certain embodiments include devices for delivering a condensation aerosol to a subject comprising a dispensing unit and a separable cartridge. In certain embodiments, the dispensing unit comprises a first housing comprising a receptacle for a separable cartridge; a controller for controlling vaporization of the substance; and a power source. In certain embodiments, the separable cartridge comprises a second housing; an airway contained within the housing having an inlet, and an outlet; a mouthpiece coupled to the outlet; an air bypass hole coupled to the outlet; at least one electrically resistive heating element disposed within the airway; a substance disposed on the at least one heating element; and an actuation mechanism configured to transfer energy from the power source to the at least one heating element; wherein an airflow from the inlet to the outlet of the airway causes the substance to vaporize and condense in the airflow to form a condensation aerosol.
- Certain embodiments include methods of entraining a vaporized substance or aerosol particles into an airflow, methods of producing a condensation aerosol, and methods of administering a substance to a subject using the devices disclosed herein. For purposes herein, “entrain” or “entraining” means to direct, lift, draw in or along, inject, transport, carry, or suspend a vaporized substance or aerosol particle into an airflow.
- Other embodiments will be apparent to those skilled in the art from consideration and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only.
- It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of certain embodiments, as claimed.
-
FIG. 1A is a schematic illustration showing deposition of a substance on downstream surfaces. -
FIG. 1B is a schematic illustration showing the use of an airflow through a plurality of holes to entrain a substance into an airflow and thereby minimize deposition of the substance on downstream surfaces according to certain embodiments. -
FIGS. 2A-2F are schematic illustrations showing examples of airflow routing in a device for entraining a condensation aerosol particle into an airflow according to certain embodiments. -
FIG. 3 is an isometric diagram of a separable cartridge for an electric multi-dose condensation aerosol delivery device. -
FIG. 4 shows the airflow rate in the airway for different total airflow rates for a cartridge. -
FIG. 5 is a schematic cross-sectional illustration of a separable cartridge for an electric multi-dose condensation aerosol delivery device showing the routing of the airflow according to certain embodiments. -
FIGS. 6A and 6B show views of a structure separating the first airway and the second airway according to certain embodiments. -
FIG. 7 is a isometric view of an electric multi-dose condensation aerosol delivery device. -
FIG. 8 is a cut-away isometric view of a portion of an electric multi-dose condensation aerosol delivery device. -
FIG. 9 is an isometric view of a dispensing unit for an electric multi-dose condensation aerosol delivery device. -
FIG. 10 is a schematic illustration showing a view of an arched metal foil according to certain embodiments. -
FIGS. 11A-D show an example of the distortion of a flat metal foil, and an arched metal foil before and during resistive heating. -
FIG. 12 is a partial cross-sectional view of a separable cartridge including air routing according to certain embodiments. -
FIG. 13 is a block diagram of an embodiment the electrical functions for an electric multi-dose condensation aerosol delivery device. -
FIG. 14 shows the particle size distribution of a condensation aerosol comprising a substance emitted from an electric multi-dose condensation aerosol delivery device according to certain embodiments. -
FIG. 15 shows the reproducibility of the amount and purity of doses of fentanyl emitted from a new, an opened, and a partially-used electric multi-dose condensation aerosol delivery device according to certain embodiments. -
FIG. 16 shows a temperature profile of a metal foil in an airflow according to certain embodiments. -
FIGS. 17A and 17B show the temperature uniformity of a metal foil in an airflow with fentanyl as the substance according to certain embodiments. -
FIG. 18 shows the amount of substance deposited on downstream heating elements from vaporized substances from preceding heating elements for different airflow velocities with little or no airflow directed upward from underneath the heating elements. -
FIG. 19 shows the amount of substance deposited on downstream heating elements from vaporized doses with a percentage of the total airflow directed upward from underneath the heating elements, where the airflow distribution was controlled by a layer of foam between the first and second airways. -
FIGS. 20A and 20B show a relationship between the temperature of a metal foil and the purity and amount of the dose emitted from an electric multi-dose condensation aerosol delivery device according to certain embodiments. - Unless otherwise indicated, all numbers expressing quantities and conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.”
- In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including,” as well as other forms, such as “includes” and “included,” is not limiting.
- Condensation aerosols can be formed when a gaseous substance condenses or reacts to form particulates in air or a gas. A gaseous substance can be produced when a solid or liquid substance is thermally sublimed or vaporized. Vaporization refers to a phase transition in which a substance changes from a solid or liquid state into a gaseous state. Sublimation refers to a phase transition in which a substance passes directly from a solid state to a gaseous state.
- Upon entering an airflow, a gaseous substance can cool and, at least in part depending on the temperature of the airflow, can condense to form an aerosol particle. Condensation aerosol particles not sufficiently entrained within the airflow have a greater probability of falling out of the airflow to deposit on a downstream surface.
- Inefficient entrainment of particulates within an airflow and subsequent deposition of the particulates on downstream surfaces is shown in
FIG. 1A .FIG. 1A shows anairway 10 having aninlet 11 and anoutlet 12. A plurality ofsupports 13 are located on one side ofairway 10. Plurality ofsupports 13 includesupport 14 and downstream supports 17. A substance can be disposed, for example, onsupport 14, and anairflow 15 established inairway 10 such that plurality ofsupports 13 includingsupport 14 are disposed inairflow 15. When the substance disposed onsupport 14 is released fromsupport 14 by, for example, vaporization, the substance can formcondensation aerosol particles 16 inairflow 15. As shown, when the aerosol particles are not fully entrained withinairflow 15,condensation aerosol particles 16 so formed can deposit on downstream supports 17. - A schematic illustration of a device for entraining a particulate, and in particular an aerosol-forming gas phase substance, within an airflow is shown in
FIG. 1B .FIG. 1B shows afirst airway 20 and asecond airway 21 separated by astructure 22.Structure 22 comprises a plurality of holes fluidly connectingfirst airway 20 andsecond airway 21. A plurality ofsupports 28 includingupstream support 24, anddownstream supports 27 are disposed on the surface ofstructure 22 withinfirst airway 20. As inFIG. 1A , a substance can be disposed, for example, onupstream support 24. Afirst airflow 25 can be established infirst airway 20, and asecond airflow 26 can be established insecond airway 21 such thatsecond airflow 26 passes fromsecond airway 21 tofirst airway 20 through the plurality of holes as indicated by theupward pointing arrows 23. Upon passing through the plurality of hole,second airflow 26 can provide a flow of air directed toward plurality ofsupports 28, includingupstream support 24 and directed towardairflow 25. The flow ofair 23 directed towardairflow 25 can act to lift a substance vaporized fromupstream support 24 to formcondensation aerosol particles 19 comprising the substance, and entrain the condensation particles withinfirst airflow 25. Entrainment ofcondensation particles 19 withinfirst airflow 25 will reduce the likelihood that thecondensation particles 19 will become deposited on the downstream surfaces 27. As shown inFIG. 1B , by entraining the condensation particles near the center offirst airflow 25, more of the condensation particles can be emitted as an aerosol from theoutlet 29 of the device and be available, for example, for administration to a subject by inhalation. - Another embodiment of a device for entraining a substance, and in particular, a gas phase substance, within an airflow to form a condensation aerosol is schematically illustrated in
FIG. 2A .FIG. 2A shows another scheme for routing an airflow through a plurality of holes and across a surface of a structure.FIG. 2A shows a device having afirst airway 30, asecond airway 31, and astructure 32 separatingfirst airway 30 andsecond airway 31. Althoughstructure 32 is shown as comprising two parts, e.g., as indicated by the thick and thin lines,structure 32 can comprise one part or multiple parts.Structure 32 includes a plurality ofholes 39 which fluidly connectfirst airway 30 andsecond airway 31.First airway 30 andsecond airway 31 are further defined byhousing 34.Housing 34 includes anair intake 35 to allowairflow 36 to entersecond airway 31, and anair outlet 37 to allowairflow 36 to exit the device. As shown inFIG. 2A ,first airway 30 andsecond airway 31 are further fluidly connected through holes and/or slots dimensioned to permit a greater, less than, orequal portion 38 ofairflow 36 to pass intofirst airway 30, compared to the portion of airflow the airflow that passes through plurality ofholes 39. The relative amounts of airflow to each airway can be altered to suit the desired purpose. In the same manner as described forFIG. 1B , the airflow through plurality ofholes 39 as indicated bysmall arrows 33, entrains the vaporized substance and thecondensation particles 41 formed by condensation of the vaporized substance released from the plurality ofsupports 40 disposed onstructure 32 withinairflow 36. Entrainment ofcondensation particles 41 withinairflow 36 reduces deposition of thecondensation particles 41 on downstream surfaces. - Another embodiment of a device for entraining a substance or condensation particles within an airflow is shown in
FIG. 2B .FIG. 2B shows a device similar to that ofFIG. 2A wherein asecond airflow 42, which is a portion ofairflow 36, enters athird airway 43.Second airflow 42 can then pass through the plurality ofholes 39 to provide an airflow directed toward a plurality ofsupports 40 and thefirst airway 30. Thecondensation particles 41 formed by vaporizing a substance disposed on the supports becomes entrained inairflow 36, which includesairflows - In another embodiment, as shown in
FIG. 2C , a portion offirst airflow 36 is directed through aporous element 44. On passing throughporous element 44, this portion of airflow passes betweensupports 40 and directs the airflow towardfirst airway 30.Porous element 44 can be fabricated from any material and have any pore size capable of distributing an appropriate portion of the air entering the device through the plurality of holes formingporous element 44. For example, in certain embodiments,porous element 44 can be an open cell foam, a mesh, a fibrous material, a glass frit, a ceramic filter, a microporous element, and the like. - How effectively a substance is entrained within an airflow can at least in part depend on the proportion of rate of airflow across the surface of a support, R1 to the rate of airflow through the plurality of openings, R2. The appropriate proportion R1:R2 for effectively entraining a substance within an airflow can depend on a number of factors such as the airflow velocity and the distance of the support from the center of the airflow. In certain embodiments, R1:R2 can range from 80:20 to 20:80 and in other embodiments can range from 60:40 to 40:60. The proportion R1:R2 can be established by the relative areas of the holes through which the first an second airflows pass. For example, referring to
FIG. 2A , a proportion of 60:40 means that the relative area of hole/slot through which airflow 38 passes is 60 and the relative area of the plurality ofholes 39 is 40. - Another embodiment of a device for entraining a substance in an airflow is shown in
FIG. 2D .FIG. 2D showsairflow 36 entering the device. One portion ofairflow 36 passes through a plurality ofholes 39 and across a plurality of supports 40. A second portion ofairflow 36 is diverted around the plurality of holes (shown onFIG. 2D as 38). The airflow portion that goes through the plurality ofholes 39 andsecond airflow portion 38 recombine infirst airway 30 and pass throughmouthpiece 45 to exit the device. - In the embodiments shown in
FIGS. 1B and 2A -D by introducing air from below the supports redeposition of the vaporized substance or aerosol condensation particles is minimized. - Different arrangements of the supports with respect to the airflow through the device are shown in
FIGS. 2E and 2F . InFIG. 2E ,airflow 36 entersfirst airway 30.Airflow 36 is routed over a plurality ofsupports 40 and recombines to pass throughmouthpiece 45 to exit the device. InFIG. 2F ,airflow 36 enteringfirst airway 30 passes over plurality ofsupports 40 to pass throughmouthpiece 45 to exit the device. - The concepts underlying the exemplary devices illustrated in
FIGS. 1B, 2A-2F can be applied to devices for administering a condensation aerosol to a subject. A subject includes mammals and humans. A cartridge for administering multiple doses of a condensation aerosol to a subject which employs airflow through a plurality of holes to facilitate entrainment of a substance released from a support within an airflow is illustrated inFIG. 3 . An exploded assembly view of such a cartridge is shown inFIG. 3 aspart 50. A cross-sectional view of an assembled cartridge is also illustrated inFIG. 5 . -
FIG. 3 shows an isometric assembly view of a cartridge capable of producing multiple doses of a substance for pulmonary administration. Thecartridge 50 illustrated inFIG. 3 comprises afirst shell 52 and asecond shell 54 which can be coupled to form a housing. When assembled, one end offirst shell 52 andsecond shell 54 form amouthpiece 56 for insertion in a subject's mouth. Anair bypass hole 58 is located adjacent tomouthpiece 56 insecond shell 54 to enable air to entermouthpiece 56 when the rate of airflow generated by inhalation exceeds the rate of airflow controlled by anair inlet valve 62 entering the cartridge. Theair inlet valve 62 can assist in minimizing any air flow variation from user to user. The rate of airflow in the housing can impact particle size and thus controlling air flow variation allows for more control over the particle size generated. Theairbypass hole 58 allows for flexibility in that it allows the user to breath at a comfortable rate without upsetting the amount of air flow that moves through the housing and across the surface of the supports. For example, a person typically inhales at a flow rate ranging from 30 L/min to 100 L/min A device, however, may have a flow rate of 6 L/min, which refers to the volume of air per time entering the device, being directed across the surface of the supports and emitted from the device, the excess airflow from the person will enterbypass hole 58.Second shell 54 further comprises an air intake 60 (partially hidden).Air intake 60 includesair inlet valve 62 that fits intoreceptacle 64 ofsecond shell 54. As discussed above,air inlet valve 62 controls the airflow rate of the cartridge and can be any valve that can control the amount of air entering the device during a single inhalation by a user. Examples of appropriate valves include flapper valves (a flexible value that bends in response to a pressure differential), umbrella valves, reed valves, or flapping valves that bend in response to a pressure differential, and the like. The purpose ofair inlet valve 62 is to control the amount of air entering the cartridge regardless of the total airflow rate during and among inhalations. The total airflow rate includes the airflow rate throughair intake 60 andair inlet valve 62, and the airflow rate throughair bypass hole 58. -
FIG. 4 demonstrates that a simple flap valve can be used to control the airflow rate through the cartridge to about 6 L/min for total inhalation ranging from 20 L/min to 90 L/min. To generate the results presented inFIG. 4 , a cartridge was fitted with a flap valve and the airflow rate through the cartridge for various total airflow rates was measured. Thus, by usingair inlet valve 62, the airflow rate through the cartridge can be relatively independent of the airflow rate generated by an inhalation. As disclosed herein, flow control can be used to control the particle size and particle size distribution of the condensation aerosol emitted from the device. However, particle size and particle size distribution can be impacted by a number of additional factors including, for example, the substance, the vaporization temperature of the substance, the temperature of the airflow and the cross-sectional air of the airway. Thus, the airflow rate can be one of several parameters to be adjusted to produce a desired average particle size and particle size distribution. In certain embodiments,air control valve 62 can be designed to control the airflow through the cartridge between 4 L/min and 8 L/min. In certain embodiments, an airflow control valve can be activated electronically such that a signal provide by a transducer located within the airway can control the position of the valve, or passively, such as, for example, by a pressure differential between the airway and the exterior of the device. Additionally, the cross-sectional area of the airway can be adjusted to produce a desired average particle size and particle size distribution. In certain embodiments the cross-section area of the airway ranges from 0.5 cm2 to 3 cm2. - As shown in
FIG. 3 ,second shell 54 further includes abreath actuation mechanism 67.Breath actuation mechanism 67 is electrically coupled to a remotely located controller (not shown) and can send a signal to the controller that interprets the data and activates the generation of a condensation aerosol when a certain pre-established airflow velocity is sensed.Breath actuation mechanism 67 can be, for example, a thermistor, which senses temperature in response to airflow.First shell 52 andsecond shell 54 also include areceptacle 68 for retainingelectrical connector 70. In addition, there can be acounter 66, which identifies the number of supports that have not been actuated in that they have not been heated yet to vaporize the substance contained thereon. - When
cartridge 50 is assembled, astructure 72 separates a first airway and a second airway.First airway 74 andsecond airway 76 are formed bystructure 72 and the opposing inner walls of first andsecond shells FIG. 5 . As shown inFIG. 3 ,structure 72 is a printed circuit board enabling electrical connection betweenconnector 70 and a plurality of electricallyresistive heating elements 78.Heating elements 78 are mounted onspacer 80 and soldered to interconnection lands 82 disposed onstructure 72.Spacer 80 can be a thermally insulating material such as, for example, a printed circuit board material. - As shown in
FIG. 3 ,structure 72 includes a plurality ofholes 84 extending over most of the surface ofstructure 72. Each of theholes 84 extends through the thickness ofstructure 72.Structure 72 also includes a set ofslots 86 near the end ofstructure 72 on whichconnector 70 is mounted. The number and dimensions of plurality ofholes 84 and set ofslots 86 determine the relative proportion of air which flows through the plurality ofholes 84 and set ofslots 86 when a subject inhales onmouthpiece 56. As shown inFIG. 5 , when a subject inhales onmouthpiece 56 ofcartridge 50, anairflow 88 is generated such that air entersair intake 60, the flow of air entering the device is controlled byair inlet valve 62 to entersecond airway 76. A first portion of airflow passes fromsecond airway 76 through a set ofslots 86 intofirst airway 74 to be inhaled by a subject. At the same time, a second portion of airflow passes through plurality ofholes 84 and entersfirst airway 74 to be inhaled by the subject. The airflows passing through the plurality ofholes 84 and the set ofslots 86 combine to pass throughmouthpiece 56 to exit the device. - A top view showing the positioning of plurality of
holes 84 and set ofslots 86 with respect to plurality ofsupports 78 is shown inFIGS. 6A and 6B .FIG. 6A showsstructure 72 comprisingconnector 70, set ofslots 86 and plurality ofholes 84. Set ofslots 86 are shown as rectangular slots. However, set ofslots 86 can have any number of openings, shapes, and/or dimensions as appropriate to cause a vaporized substance to become entrained within the airflow so as to form a condensation aerosol that exhibits appropriate properties for inhalation administration. Plurality ofholes 84 is shown as comprising a regular array of round openings. However, plurality ofholes 84 can have any number of openings, shapes, and/or dimensions as appropriate to cause a vaporized substance and condensation aerosol particles to be entrained within the airflow to form a condensation aerosol exhibiting appropriate properties for inhalation administration. For example, each row ofholes 88 can instead be a narrow slot. Plurality ofholes 84 can also be placed in a different arrangement over the surface ofstructure 72. - As shown in
FIG. 6B , in certain embodiments, holes 84 can be positioned beneathgaps 90 betweenadjacent heating elements 78. Air flowing fromholes 84 throughgaps 90 can direct a substance released fromsupports 78 into an airflow. In certain embodiments, at least some of the plurality ofholes 84 can be located beneath at least some of thesupports 78. - A cartridge as described in
FIGS. 2-6 can be used in a condensation aerosol delivery device for the administration of a physiologically active substance to a subject. A solid view of an exemplary condensationaerosol delivery device 100 according to the disclosure is shown inFIG. 7 . An isometric view with the top of the device and the cartridge removed is shown inFIG. 8 , and an exploded isometric view of the condensationaerosol delivery device 100 is shown inFIG. 9 . Referring toFIG. 9 , the condensationaerosol delivery device 100 includescartridge 50 and adispensing unit 102. As shown inFIG. 9 cartridge 50 can be a separable unit. In certain embodiments,cartridge 50 can be an integral component of dispensingunit 102.Dispensing unit 102 includes afirst shell 104 and asecond shell 106 which can be assembled to form the housing of dispensingunit 102. As shown inFIG. 9 , dispensingunit 102 further includes abattery power source 108, and a printedcircuit board 110 incorporating amicroprocessor controller 112, adisplay 114, and aconnector 116 for connecting the dispensing unit with the cartridge and which also connects tocontroller 112 andpower source 108 comprising three AAA batteries tocartridge 50. - To deliver a condensation aerosol to a subject, the
subject places mouthpiece 56 of condensationaerosol delivery device 100 into his or her mouth. The subject then inhales onmouthpiece 56 to generate an airflow as described herein. When a certain minimum airflow or a rate in change in airflow is sensed, the device is triggered. A signal from the airflow sensor is sent to the controller to cause the battery power source to connect to at least one support. As described herein, the supports can be, for example, electrically resistive heating elements. Heat produced by the electrically resistive heating element thermally vaporizes the substance disposed thereon. The vaporized substance condenses in the airflow to form condensation particles and hence, a condensation aerosol. As described herein, the airflow passing from beneath the heating element causes the substance vaporized from the heating element or the condensed aerosol particles to become entrained in the airflow as opposed to depositing on other supports prior to passing through the cartridge. The aerosol upon passing through the cartridge is subsequently inhaled by the subject. Activation of the condensation aerosol delivery device, generation of the condensation aerosol, and inhalation of the condensation aerosol can occur in a single breath. The inhaled condensation aerosol then enters the subject's respiratory tract where the condensation aerosol comprising the active substance can be deposited in the respiratory tract, and in particular the pulmonary alveoli, of the subject. - A device for generating a condensation aerosol can include at least one support and in certain embodiments, for example, as shown in
FIGS. 2-5 and 8 , can include a plurality of supports. The supports can provide a surface and/or structure on which a substance to be released into an airflow can be disposed. In certain embodiments, the supports can be located at a side of the airway, for example on the surface of the structure, or can be located toward, near, or in the center of the airway. The shape and dimensions of the supports, and the material or materials forming the supports can be chosen to facilitate release of a substance disposed on the supports upon the application of energy, to minimize degradation of the substance during release, to cause rapid heating of the substance disposed thereon and/or to minimize the amount of energy used to release the substance. - Selection of the appropriate material for forming the support can also, at least in part, be determined by the source of energy used to release the substance from the support. For example, the source of energy used to release the substance can be mechanical, acoustic, radiation such as microwave, radio frequency or optical, and/or thermal. When the applied energy is absorbed directly by the substance, the support can be non-thermally conductive. For example, an optical source can be used to ablate and/or vaporize a substance disposed on a support. Alternatively, in certain embodiments, it can be more efficient or practical to heat a thermally conductive support which transfers thermal energy to the substance disposed thereon to release the substance from the support. In such embodiments, the support can be a thermally conductive material such as a metal, a metal alloy, a metal composite having more than one layer and/or composition, graphite, or the like. For example, in certain embodiments the metal can be stainless steel, copper, nickel, aluminum, gold, or silver, and can be plated with one or more of the foregoing materials or other metals. In some embodiments, the thickness of the plating of a metal layer on the metal can be within the range of between 0.001 μm to 3 μm and in other embodiments. In some embodiments, the support can be a semi-conducting material.
- In certain embodiments, for example, where the condensation aerosol delivery device is designed for portable use with a battery power source, efficient energy use can be desirable. Minimization of the energy used to release a substance from a support can, at least in part, depend on the shape and dimensions of the support, the materials forming the support, and the placement of the support within the airway. In certain embodiments, the support can comprise an electrically resistive material such as a foil. In certain embodiments, the foil can be a stainless steel foil and can include a layer of one or more materials such as a gold layer to facilitate, for example, forming an electrical connection, and/or modifying the electrical properties such as the resistance of a portion of the foil. The appropriate dimensions for a foil can depend at least in part, on the desired resistance, the amount of substance disposed on the support, the amount of energy needed to vaporize the substance disposed on the support, and/or on mechanical stability considerations.
- To maximize transfer of thermal energy produced by the support to the substance disposed thereon, it is desirable that a thermally conductive support be thermally isolated. Minimizing the contact area between the support and the connector helps to thermally isolate the support. As shown, for example, in
FIG. 3 , thermal isolation can be accomplished by suspending the support in the airflow above the surface of the structure by means of a spacer whereby the ends of the metal foil can be electrically connected to the power source. As shown inFIGS. 3, 8 and 10 , in certain embodiments, the metal foil can be arched. During heating, thin foils can have a tendency to distort. This phenomenon is schematically illustrated inFIG. 11 , where a metal foil is shown suspended between two conductors.FIG. 11(a) shows a flat metal foil spanning two conductors. During heating, the flat metal foil can distort as shown schematically inFIG. 11(b) . In a multiple dose condensation aerosol delivery device comprising several metal foil supports, such mechanical distortion of the foils can interact with the airflow to increase deposition of the condensation aerosol particles on downstream surfaces. To facilitate the accuracy and reproducibility of the amount of substance released upon firing from each support or heating element and transferred to recipient, it can be desirable that the airflow characteristics of the device be consistent for each actuation of the device. While distortion of a metal foil can be minimized by using thicker foils, efficient heating of the metal foils with minimum power consumption indicates the use of thin foils. It has been found that the mechanical stability of a metal foil can be improved by producing a slight arch in the foil. An example of an arched foil is shown inFIG. 11(c) . During heating, the arched metal foil shown inFIG. 11(c) can exhibit a slight upward movement as indicated inFIG. 11(d) , and following heating returns to approximately the same arched configuration as prior to heating. The arch can be formed a number of ways, such as, for example, but not limitation, assembly by placing the metal foil, or plurality of metal foils over an arched mandrel and bonding the ends to a platform. The metal foil can be too thin to take a permanent set, but can be held in slight compression to maintain the arch. The platform on which the arched metal foil is mounted can be for example, a spacer such asspacer 80 as shown inFIG. 3 , or can bestructure 72 separating the first and second airways in embodiments where a spacer is not employed. In some embodiments of the invention, the height of the arch can ranges from 0.5 mm to 2 mm. - Particularly for portable, battery operated condensation aerosol delivery devices, it can be useful to minimize the amount of power used to vaporize a substance. Several characteristics of the metal foil can be chosen to facilitate the efficient thermal vaporization of a substance from a metal foil, including, but not limited to, the thickness of the metal foil, the impedance of the metal foil, and the ratio of the surface area to the thermal mass of the metal foil. In certain embodiments, the thickness of the metal foil can be less than 0.01 inches, in certain embodiments, less than 0.001 inches, and in certain embodiments, less than 0.0005 inches. To minimize power dissipation in the electrical circuit and thereby maximize power delivered to the heating element, it can be desirable that the impedance of the metal foil be closely matched to the impedance of the power source. For example, in certain embodiments, the difference between the impedance of the resistive heating element and the impedance of the power source can be less than 50% of the impedance of the power source, in certain embodiments, less than 10% of the impedance of the power source, and in certain embodiments, less than 2% of the impedance of the power source. To facilitate the efficient transfer of thermal energy produced by the resistive heating element to the substance disposed thereon, it can be useful to maximize the ratio of the surface area of the resistive heating element to the thermal mass of the resistive heating element. Accordingly, in certain embodiments the ratio of the surface area of the heating element to the thermal mass of the resistive heating element can be greater than 10 cm2/J/° C., in certain embodiments, greater than 100 cm2/J/° C., and in certain embodiments, greater than 500 cm2/J/° C.
- Low ratios of the surface area of the heating element to the thermal mass of the resistive heating element can facilitate the transfer of heat to the substrate, and lead to rapid thermal vaporization of the substance. Rapid thermal vaporization of a substance can minimize thermal degradation of the substance during vaporization and thereby maximize the purity of the condensation aerosol formed therefrom. For example, in certain embodiments, the support, and in particular, a metal foil can be heated to a temperature of at least 250° C. in less than 500 msec, in certain embodiments, to a temperature of at least 250° C. in less than 250 msec, and in certain embodiments, to a temperature of at least 250° C. in less than 100 msec.
- Efficient transfer of thermal energy produced by the resistive heating element to the substance disposed thereon can further be facilitated by the substance being disposed on the surface as a thin layer. For example, in certain embodiments, the thickness of the layer of substance can range from 0.01 μm to 50 μm, in certain embodiments, can range from 0.01 μm to 20 μm, and in certain embodiments, can range from 0.01 μm to 10 μm.
- The amount of energy to thermally vaporize a substance can be minimized by, for example, using an electrically resistive heating element comprising a thin metal foil, closely matching the impedance of the electrically resistive heating element to the impedance of the power source, maximizing the ratio of the surface area of the resistive heating element to the thermal mass of the resistive heating element, and using a thin film of substance disposed on the heating element. By appropriate design and selection of at least the foregoing parameters, in certain embodiments, the amount of energy to vaporize a substance from a support can be less than 250 joules, in certain embodiments, less than 50 joules, and in certain embodiments, less than 10 joules. In more specific embodiments, the amount of energy to vaporize one mg of substance from a support can be less than 250 joules, in certain embodiments, less than 50 joules, and in certain embodiments, less than 10 joules.
- The number of supports forming a condensation aerosol delivery device and/or cartridge is not particularly limited. For example, in certain embodiments, a cartridge or drug delivery device can comprise from 1 to 200 supports, in certain embodiments, from 1 to 50 supports, and in certain embodiments, from 1 to 25 supports, and in certain embodiments, from 1 to 10 supports.
- The cartridge can be separable from the condensation aerosol delivery device. In such embodiments, a subject can use the delivery device, for example, to administer more than one physiologically active substance, or more than one dose of the same physiologically active substance by replacing one cartridge with another. Also, when all the doses in a particular cartridge are exhausted, the user can obtain and insert a new cartridge into the delivery device.
- While certain embodiments of the present disclosure can comprise a single support, it is contemplated that embodiments comprising a plurality of supports can be particularly useful in, for example, providing a convenient method of delivering multiple doses of a physiologically active compound or drug over a period of time. The terms physiologically active compound and drug are used interchangeably herein. As used herein, a drug refers to a substance recognized in an official pharmacopoeia or formulary, and/or a substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease where disease refers to any disease, disorder, condition, symptom or indication. In such embodiments, the substance disposed on at least one support can comprise a therapeutically effective amount of a drug. For example, a therapeutically effective amount or dose of a drug can be disposed on a single support, on each of multiple supports, or on more than one support. In certain embodiments of a condensation aerosol delivery device, the same amount of physiologically active compound can be disposed on each support. In certain embodiments, different amounts of a physiologically active compound can be disposed on each of the plurality of supports, or a certain amount of active compound can be disposed on several supports, and a different amount of active compound on several other supports. Having different amounts of a drug on different supports can be useful in effecting treatment regimens where administering a variable amount of drug during a period of time is useful.
- In certain embodiments, where the active compound disposed on several supports is an abusable substance, a second compound comprising an agonist can be disposed on one or more other supports. “Abusable substance” refers to a substance that can be improperly used, for example, by administering more than a prescribed or intended dosage, or by altering the route of administration from the intended route. For example, an opioid analgesic can be abused by using the opioid analgesic to elicit a euphoric effect, rather than therapeutically for the treatment of pain. Abusable substances include substances regulated by a regulatory agency focused on preventing drug abuse, such as, for example, the United States Drug Enforcement Agency (DEA). In certain embodiments, an abusable substance can be a substance listed on DEA schedule II, III, IV, or V. The second compound is a chemical compound that can act to reduce or to counteract the physiological activity and/or pharmacological effects of another chemical substance. Having both an abusable substance and a second compound capable of counteracting the effects of the abusable substance in the same device will complicate the ability of an abuser to selectively remove the abusable substance from heating elements. Proper use of the device would only allow the abusable substance to be activated in prescribed doses.
- A substance to be released can be disposed on at least one surface of a support. For example, the substance can be disposed on the surface facing the center of the first airway and/or toward the part of the airflow where the velocity is highest. The substance can be applied to a surface of a support by any appropriate method and can depend at least in part on the physical properties of the substance and the final thickness of the layer to be applied. In certain embodiments, methods of applying a substance to a support include, but are not limited to, brushing, dip coating, spray coating, screen printing, roller coating, inkjet printing, vapor-phase deposition, spin coating, and the like. In certain embodiments, the substance can be prepared as a solution comprising at least one solvent and applied to a support. In certain embodiments, a solvent can comprise a volatile solvent such as acetone, or isopropanol. In certain embodiments, the substance can be applied to a support as a melt. In certain embodiments, a substance can be applied to a film having a release coating and transferred to a support. For substances that are liquid at room temperature, thickening agents can be admixed with the substance to produce a viscous composition comprising the substance that can be applied to a support by any appropriate method, including those described herein. In certain embodiments, a layer of substance can be formed during a single application or can be formed during repeated applications to increase the final thickness of the layer. In other embodiments, the substance can be applied on more than one surface of the support.
- In certain embodiments, more than one active compound can be disposed on one or more of the plurality of supports. For example, a first active compound can be disposed on certain supports, and a second active compound can be disposed on other supports, and in certain embodiments, a composition comprising a first active compound and a second active compound can be disposed on one or more supports.
- A dose can correspond to the amount of active compound released from a single support, or the amount of active compound released from more than one support. A dose or dosage as used herein refers to the amount of substance released during a single activation of a condensation aerosol delivery device. A dose can comprise a therapeutically amount of a physiologically active compound, meaning that the dose provides effective treatment of a condition and/or disease in a patient. The therapeutically effective amount of a physiologically active compound can vary from compound to compound, from subject to subject, and can depend upon factors such as the condition of the subject.
- In certain embodiments, a substance disposed on at least one support can comprise a therapeutically effective amount of at least one physiologically active compound or drug. A therapeutically effective amount refers to an amount sufficient to effect treatment when administered to a patient or user in need of treatment. Treating or treatment of any disease, condition, or disorder refers to arresting or ameliorating a disease, condition or disorder, reducing the risk of acquiring a disease, condition or disorder, reducing the development of a disease, condition or disorder or at least one of the clinical symptoms of the disease, condition or disorder, or reducing the risk of developing a disease, condition or disorder or at least one of the clinical symptoms of a disease or disorder. Treating or treatment also refers to inhibiting the disease, condition or disorder, either physically, e.g. stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both, and inhibiting at least one physical parameter that may not be discernible to the patient. Further, treating or treatment refers to delaying the onset of the disease, condition or disorder or at least symptoms thereof in a patient which may be exposed to or predisposed to a disease, condition or disorder even though that patient does not yet experience or display symptoms of the disease, condition or disorder. In certain embodiments, the amount of substance disposed on a support can be less than 100 micrograms, in certain embodiments, less than 250 micrograms, in certain embodiments, less than 500 micrograms, and in certain embodiments, less than 1,000 micrograms.
- When delivering a pharmaceutical compound to a subject, the amount of substance that is vaporized off the surface is important. Consistency of delivery of the compound is also critical. In certain embodiments, at least 80% of the amount of material disposed on each support passes through the outlet of the device for deliver to the subject, in other embodiments, at least 90% passes through the outlet, and in other embodiments, at least 98% passes through the outlet.
- In certain embodiments, a substance can comprise a pharmaceutical compound. In certain embodiments, the substance can comprise a therapeutic compound or a non-therapeutic compound. A non-therapeutic compound refers to a compound that can be used for recreational, experimental, or pre-clinical purposes. Classes of drugs that can be used include, but are not limited to, anesthetics, anticonvulsants, antidepressants, antidiabetic agents, antidotes, antiemetics, antihistamines, anti-infective agents, antineoplastics, antiparkinsonian drugs, antirheumatic agents, antipsychotics, anxiolytics, appetite stimulants and suppressants, blood modifiers, cardiovascular agents, central nervous system stimulants, drugs for Alzheimer's disease management, drugs for cystic fibrosis management, diagnostics, dietary supplements, drugs for erectile dysfunction, gastrointestinal agents, hormones, drugs for the treatment of alcoholism, drugs for the treatment of addiction, immunosuppressives, mast cell stabilizers, migraine preparations, motion sickness products, drugs for multiple sclerosis management, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics and stimulants, ophthalmic preparations, osteoporosis preparations, prostaglandins, respiratory agents, sedatives and hypnotics, skin and mucous membrane agents, smoking cessation aids, Tourette's syndrome agents, urinary tract agents, and vertigo agents.
- Examples of pharmaceutical compounds include fluticasone propionate, clonidine, triazolam, albuterol, ciclesonide, fentanyl, terbutaline, flumazenil, triamcinolone acetonide, flunisolide, ropinirole, alprazolam, buprenorphine, hyoscyamine, atropine, pramipexole, bumetanide, flunitrazepam, oxymorphone, colchicine, apomorphine HCl, granisetron, pergolide, nicotine, loperamide, azatadine, naratriptan, clemastine, benztropine, ibutilide, butorphanol, fluphenazine, estradiol-17-heptanoate, zolmitriptan, metaproterenol, scopolamine, diazepam, tolterodine, estazolam, haloperidol, carbinoxamine, estradiol, hydromorphone, bromazepam, perphenazine, midazolam, methadone, frovatriptan, eletriptan, testosterone, melatonin, galanthamine, cyproheptadine, bropheniramine, and chlorpheniramine. In certain embodiments, the compound is chosen from alprazolam, buprenorphine, clonindine, fentanyl, midazolam, pramipexole, ropinirole, and triazolam. In certain embodiments, the compound is chosen from a compound for the treatment of pain. In certain embodiments, the compound for the treatment of pain is fentanyl.
- In certain embodiments, a drug can further comprise substances to enhance, modulate and/or control release, aerosol formation, intrapulmonary delivery, therapeutic efficacy, therapeutic potency, stability, and the like. For example, to enhance therapeutic efficacy a drug can be co-administered with one or more active agents to increase the absorption and/or diffusion of the first drug through the pulmonary alveoli, or to inhibit degradation of the drug in the systemic circulation. In certain embodiments, a drug can be co-administered with active agents having pharmacological effects that enhance the therapeutic efficacy of the drug. In certain embodiments, a drug can comprise compounds that can be used in the treatment of one or more diseases, conditions, or disorders. In certain embodiments, a drug can comprise more than one compound for treating one disease, condition, or disorder, or for treating more than one disease, condition, or disorder.
- In certain embodiments, the substance can comprise one or more pharmaceutically acceptable carriers, adjuvants, and/or excipients. Pharmaceutically acceptable refers to approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
- In general, substances useful in embodiments of the disclosure can exhibit a heat of vaporization less than about 150 kJoules/mol.
- Not only can the amount of compound forming a dose be impacted by deposition of aerosol particles on the device and other supports in the device, but the amount of compound forming a dose can be reduced by degradation of the active agent during release from the support. While it will be recognized that the extent and dynamics of thermal degradation can at least in part depend on a particular compound, in certain embodiments, thermal degradation can be minimized by rapidly heating the substance to a temperature sufficient to vaporize and/or sublime the active substance. In certain embodiments, the support or heating element can be heated to a temperature of at least 250° C. in less than 500 msec, in certain embodiments, to a temperature of at least 250° C. in less than 250 msec, and in certain embodiments, to a temperature of at least 250° C. in less than 100 msec.
- In certain embodiments, rapid vaporization of a layer of substance can occur with minimal thermal decomposition of the substance, to produce a condensation aerosol exhibiting high purity of the substance. For example, in certain embodiments, less than 10% of the substance is decomposed during thermal vaporization resulting in a condensation aerosol with at least 90% purity and in certain embodiments, less than 5% of the substance is decomposed during thermal vaporization resulting in a condensation aerosol with at least 95% purity, and in other embodiments, less than 2% of the substance is decomposed during thermal vaporization resulting in a condensation aerosol with at least 98% purity.
- For administration of a compound, the size of the particulates of the compound comprising the aerosol can be within a range appropriate for intrapulmonary delivery. Without being limited by theory, an aerosol having a mass median aerodynamic diameter (“MMAD”) ranging from 1 μm to 3 μm, and ranging from 0.01 μm to 0.10 μm are recognized as optimal for intrapulmonary delivery of pharmaceutical compounds. Aerosols characterized by a MMAD ranging from 1 μm to 3 μm can deposit on alveoli walls through gravitational settling and can be absorbed into the systemic circulation, while aerosols characterized by a MMAD ranging from about 0.01 μm to 0.10 μm can also be deposited on the alveoli walls through diffusion. Aerosols characterized by a MMAD ranging from 0.15 μm to 1 μm are generally exhaled. Thus, in certain embodiments, aerosols produced using devices and methods of producing an aerosol can having a MMAD ranging from 0.01 μm to 5 μm, in certain embodiments, a MMAD ranging from 0.05 μm to 3 μm, in certain embodiments, a MMAD ranging from 1 μm to 3 μm and in certain embodiments, a MMAD ranging from 0.01 μm to 0.1 μm. In certain embodiments, aerosols suitable for intrapulmonary delivery of pharmaceutical compounds can further be characterized by the geometric standard deviation of the log-normal particle size distribution. In certain embodiments, aerosols produced using the devices and methods of producing an aerosol comprise a geometric standard deviation of the log-normal particle size distribution of less than 3, in certain embodiments, less than 2.5, and in certain embodiments, less than 2.
- In certain embodiments, a cartridge can include a part disposed in the mouthpiece to control the airflow exiting the device. A partial section view of the cartridge cross-section of
FIG. 5 is shown inFIG. 12 .FIG. 12 shows the front section ofcartridge 50, further including anair routing part 200 disposed within themouthpiece 56. Theairflow 88 enteringair intake 60, andair inlet valve 62 passes through the internal airways to entrain a condensation aerosol particles, and passes through the orifice defined byair routing part 200 to be emitted from the device.Bypass airflow 202 entersbypass opening 58 and is diverted around the outside ofair routing part 200. Thefront 204 ofair routing part 200 extends to near thetip 206 ofmouthpiece 56. The use ofair routing part 200 can be useful in maintaining smooth airflow through the device and facilitating control of the condensation aerosol particle size. - An embodiment of a condensation aerosol delivery device is the portable electric multi-dose drug delivery systems discussed herein, and illustrated in
FIGS. 7 to 9 . The electric multi-dose drug delivery system is designed to produce and deliver a therapeutic condensation aerosol into the respiratory tract, and in particular to the pulmonary pathway, of a subject. As discussed herein, the condensation aerosol delivery device includes two subsystems, referred to as the cartridge and the dispensing unit. Both the cartridge and the dispensing unit incorporate several electronic features which facilitate the portability, safety, versatility, and convenience of the delivery device. As disclosed herein, the cartridge includes the therapeutic drug in individual doses, and electronics to sense airflow generated by the subject's inhalation. The dispensing unit includes a battery power source, and a microcontroller that controls the drug vaporization process, and can include a number of communication functions. Such communication functions include, but are not limited to, cartridge identification, dose identification, abuse prevention functions, use monitoring, and dose control. - A functional block diagram of the electronics for an exemplary embodiment of an electric multi-dose condensation
aerosol delivery device 100 is shown inFIG. 13 .FIG. 13 shows acartridge 130 comprising anEEPROM 132, abreath sensor 134, and twenty-five drug coated metal foils 136.EEPROM 132 can include, for example, an identifying serial number for the cartridge, a manufacturing date, and/or additional identification and control information, and monitors the number of doses remaining in the cartridge.EEPROM 132 is electrically connected tomicrocontroller 152 contained in thedispensing unit 150.Microcontroller 152 can read or write to EEPROM 132 to update and record the data stored therein.EEPROM 132 need not require power to maintain the data.Breath actuation sensor 134 includes circuitry for detection of airflow, and is electrically connected tomicrocontroller 152. The circuitry can comprise two temperature sensing devices such as thermistors, one of which is heated. Air flowing across theheated sensor 134 is transduced as a change in voltage, which is monitored bymicrocontroller 152. When a certain minimum velocity ofairflow 138 is sensed,microcontroller 152 connectspower source 154 to at least one of resistive metal foils 136 to effect vaporization of the drug disposed thereon. Plurality of drug coatedfoils 136 are electrically connected to aswitch matrix 156 which is controlled bymicrocontroller 152. As disclosed herein, plurality of drug coatedfoils 136 can be selectively heated by passing a current through the foils to vaporize the drug coating to form a condensation aerosol inairflow 138. - As shown in
FIG. 13 , dispensingunit 150 includesmicrocontroller 152,power source 154,switch matrix 156, a hardware safety lock-outmechanism 158, a user-activatedswitch 160, and a liquid crystaldisplay user interface 162.Microcontroller 152 incorporates embedded software and controls operation of the condensation aerosol delivery device. When not operating,microcontroller 152 is maintained in a sleep mode to conserve power consumption. Upon momentary depression ofuser activation switch 160,microcontroller 152 becomes operational. In certain embodiments,microcontroller 152 can also be activated by inserting a cartridge into the delivery device.Microcontroller 152 can then check for the presence ofcartridge 130, and if present,microcontroller 152 readsEEPROM 132 to determine whether the serial number ofcartridge 130 matches the serial number stored in the controller, and calculates the number of unused doses contained on drug coatedfoils 136 remaining incartridge 130. A purpose of matching the cartridge and dispensing unit serial number can be to personalizeindividual cartridges 130 and dispensingunit 150 to an individual patient. Personalization can be programmed using the embedded software by a health care provider to facilitate and personalize a patient's treatment regimen, and to reduce the potential for abuse by preventing a particular cartridge from being used in a dispensing unit having a different serial number. Upon verification of the parameters,microcontroller 152 updates display 162 with, for example, the number of doses remaining incartridge 130, and waits for an activation signal frombreath sensor 134. When a patient establishes a sufficient airflow incartridge 130 by inhaling on the cartridge mouthpiece,microcontroller 152 connectspower source 154, throughswitch matrix 156, to one or more of drug coatedfoils 136 to release the drug to form a condensation aerosol comprising the drug inairflow 138 ofcartridge 130 that is inhaled by the patient.Microcontroller 152 is electrically connected to switchmatrix 156, and can connect one or more of drug-coatedfoils 136 topower source 154 at a given time. In certain embodiments,microcontroller 152 can connect one or more drug coatedfoils 136 topower source 154 sequentially, randomly, or in a predetermined order. Following actuation to deliver a dose to the patient,microcontroller 152 can enter a lockout period in which a subsequent dose cannot be released until the lockout period expires.Microcontroller 152 can enter a sleep mode to conserve power until manually activated by depressinguser activation switch 160, inserting a cartridge in the device, and/or removing a cartridge. -
Display 162 is an electronic display which can inform a user of the current state of the device, e.g., whether the device is in the sleep or activated mode, and the number of unused doses remaining in the cartridge. User activatedswitch 160 is a momentary push button switch that when depressed activates the system from the sleep mode.Power source 154 comprises three alkaline primary cells that are used to power the system including providing the power necessary to vaporize the drug disposed on metal foils 136.Switch matrix 156 can be an array of MOSFET switches under control of the microcontroller that couple power frompower source 154 to the appropriate drug coated foils 136.Hardware safety lockout 158 is a redundant, software-independent system that can prevent more than one dose from being delivered at a time and/or prevent a second dose from being delivered before the end of the lockout period.Hardware safety lockout 158 provides a redundant safety mechanism in the event of software malfunction. - In certain embodiments, the device is such that the total airflow passing through the outlet ranges from 10 liters/min to 100 liters/min. In other embodiments, the total airflow passing though the outlet ranges from 20 liters/min to 90 liters/min.
- In certain embodiments of the device, the airflow rate through the inlet is less than 100 L/min. In other embodiments, the airflow rate through the inlet is less than 50 liters/min. In yet other embodiments, the airflow rate through the inlet is less than 25 liters/min; and in still other embodiments, the airflow rate through the inlet is less than 10 liters/min.
- It should also be evident from the various embodiments disclosed herein that many parameters can be selected and/or adjusted to provide a condensation aerosol delivery device, and in particular an electric condensation aerosol delivery device capable of delivering multiple doses of a physiologically active substance to a patient with each dose being delivered during a single inhalation. It will be appreciated that at least some of the parameters are interactive, and that the multiple parameters can be adjusted by routine optimization procedures to generate a condensation aerosol comprising a dose of a particular physiologically active substance. As discussed herein, such parameters include, but are not limited to the properties of a particular substance, e.g., heat of vaporization, the quantity of substance comprising a dose, the thickness of the layer disposed on the support, the thickness of the heating element, the ratio of the surface area of the heating element to the thermal mass of the resistive heating element, and the airflow.
- Embodiments of the present disclosure can be further defined by reference to the following examples, which describe in detail certain embodiments of the present disclosure. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the present disclosure.
- Electric multiple dose condensation aerosol delivery devices as shown in
FIGS. 2-5 were fabricated. The two halves forming the housing of the cartridge were molded from either acrylonitrile-butadiene-styrene or polycarbonate. The structure separating the first and second airways was fabricated from 0.032-inch thick FR4 printed circuit board material. When assembled, the circuit board and the walls of the cartridge define a 3.5 inch long first airway having a cross-sectional area of 1.5 cm2, and a 3.0 inch long second airway having a cross-sectional area of 1.5 cm2. The total resistance through the cartridge was 0.07 sqrt(cm-H2O)/L/min at a total airflow rate of 20 L/min and 0.09 sqrt(cm-H2O)/L/min at 90 L/min. The flow valve was designed to control the flow between 4 L/min and 8 L/min for a total flow rate ranging from 20 L/min to 90 L/min (seeFIG. 4 ). Circuit boards used to separate the first and second airways were fabricated having different arrangements and dimensions of holes. In a certain exemplary embodiment, the plurality of holes beneath the metal foils comprised an array of 100 round holes situated beneath the gaps between adjacent metal foils. Sixty percent of the airflow entering the air control valve passed through a series of slots and across the heating elements in the first airway. Forty percent of the airflow passed through the plurality of holes in the circuit board and was directed toward the heating elements and the center of the first airway. - The device incorporated 25 supports. The supports were fabricated from 0.0005 inch thick stainless steel foils having a surface area of 0.2 cm2 and mounted in an arched configuration to minimize distortion during heating. Fifty μg of fentanyl was deposited on the surface of each foil by spray coating from a solution comprising either isopropyl alcohol, acetone, or acetonitrile. The 50 μg layer of fentanyl was 3 μm thick. The resistance of the metal foils on which the fentanyl was deposited was 0.4Ω, the ratio of the surface area of the metal foil to the thermal mass of the heating foil was 47 cm2/J/C. Either three AAA batteries or a Hewlett Packard 6002A DC power supply were used, depending on the experiment conducted, to provided 1.7 joules of energy to the heating element to vaporize the 50 μg of fentanyl.
- The size of aerosol particles can impact the therapeutic efficacy of a pharmaceutical administered by inhalation. For example, aerosols having a particle size ranging from 0.01 μm to 3 μm are considered optimal for pulmonary delivery. In addition to the dynamics of aerosols during inhalation, it can be important that a condensation aerosol delivery device generate a consistent and reproducible particle size distribution. Aerosol particle size can be characterized by the mass median aerodynamic diameter (MMAD) of the aerosol. MMAD refers to the median of the distribution of particle sizes forming the aerosol.
- Aerosol particle size distributions for condensation aerosols formed using the condensation aerosol delivery device described in Example 1 are presented in
FIG. 14 . Each foil of a 25-foil cartridge contained 50 μg of fentanyl as a 3 μm thick layer. A single foil was heated to a peak temperature of 400° C. within 350 msec in a 6 L/min airflow. The particle size distribution of the aerosol emitted from the device was measured by the Anderson Impaction method using an eight stage Cascade Impactor Series 20-800 Mark II (Anderson, Copley Scientific, Nottingham, UK). The particle size distribution for two replicates from each of front foils (1-5), middle foils (10-15) and back foils (20-25) (closest to the mouthpiece) are presented inFIG. 14 . The particle size distribution of the aerosol from each foil is consistent, exhibiting a range of particle size from about 5.8 μm to about 0 μm with a MMAD of 1.8 μm, and a geometric standard deviation (GSD) of 1.7 μm. - The airflow in a condensation aerosol delivery device as described in Example 1 was adjusted and the particle size of five emitted doses measured using the Anderson impaction method. The airflow volume was increased from 4 L/min to 8 L/min to increasing the airflow velocity from 1 m/sec to 2 m/sec. In tests 1, 2, and 4, a bypass air routing part was inserted into the mouthpiece section of the cartridge (to get the total airflow up to 28.3 L/min for the Andersen impactor to function properly) such that the bypass air and the airflow containing the condensation aerosol joined just prior to entering the impactor. In
test 3, however, bypass air was introduced into the outgoing airflow immediately after passing over the heating elements. The results are presented in Table 1. -
TABLE 1 Effect of Airflow Rate on Aerosol Particle Size Test 1 Test 2Test 3Test 4Airflow Rate (L/min) 4 6 6 8 Airflow Velocity (m/sec) 1 1.5 1.5 2 Percent Recovery 83 90 86 90 Emitted Dose (μg) 208 225 216 224 MMAD (μm) 2.53 1.88 1.37 1.25 GSD 1.99 2.09 2.36 2.10 FPF (1-3.5 μm) (%) 56 61 60 58 Fraction 0-2 μm (%) 37 53 69 76 Fraction <5 μm (%) 91 98 100 100 - The stability of fentanyl in multi-dose condensation aerosol delivery devices was determined by measuring the amount and purity of fentanyl in an emitted dose for a newly manufactured cartridge (diagonal lines), an unused cartridge that was stored at room temperature for 7 days (cross-hatch), and a cartridge that was used to emit 10 doses and then stored at room temperature for 7 days (solid). The results are presented in
FIG. 15 . - Three AAA batteries provided 1.7 joules of energy to a 0.0005 inch thick stainless steel foil on which 50 μg of fentanyl was deposited. The airflow velocity was 1 m/sec corresponding to an airflow rate of 4 L/min. As shown in
FIG. 16 , the temperature of the foil increased to a temperature of about 200° C. within 50 m/sec, a maximum temperature of 400° C. within 284 m/sec, and returned to room temperature within 1.5 sec after reaching maximum temperature. - The temperature uniformity of a foil having a thin layer of 50 μg of fentanyl was measured during heating. The results are shown in
FIGS. 17A and 17B . - The effects of the airflow in a cartridge on the deposition of the aerosol particles on downstream surfaces is demonstrated in
FIGS. 18 and 19 . The results presented inFIG. 18 were obtained using a cartridge as described in Example 1 with the exception that there was no circuit board separating the first and second airways and flow was controlled by flow meters instead of a flow valve. The heating elements were supported at the edges only and there was no flow control between the first and second airways; the amount of air entering the first and second airways was controlled by flow meters at the inlet to each airway. For the 1 m/s and 2 m/s examples inFIG. 18 the first and second airways were separated by a piece of tape to test aerosol particle deposition when all the airflow passed over the top of the heating elements. In the 90/10 1 m/s example, in contrast, the tape was removed and the flow meters were set such that 90% of the inlet airflow entered through the first airway and 10% entered through the second airway. The air that entered through the second airway had to flow through the gaps between the heating elements to reach the airway outlet. Finally, in the 1 m/s, tape under 16-25 case a piece of tape was placed below heating elements 16-25 and again the flow meters were set such that 90% of the inlet airflow entered through the first airway and 10% entered through the second airway. The tape was intended to increase the amount of air flowing up past heating elements 1-15. In eachexperiment heating elements FIG. 18 , for each of these conditions up to about 5 μg of fentanyl was deposited on each downstream heating element. -
FIG. 19 shows the results from three tests conducted using the same airway as described above for the results inFIG. 18 . In these tests, however, the first and second airways were separated by a thin piece of foam placed directly below the heating elements and the flow meters were set such that 50% of the inlet airflow entered through the first airway and 50% entered through the second airway. The foam created a pressure drop between the first and second airway, evenly distributing the flow from the second airway past each heating element and into the center of the first airway. In theseexperiments 50 μg of fentanyl were vaporized from each of the 25 heating elements (in contrast to the experiments fromFIG. 18 where fentanyl was only vaporized from 4 heating elements) fromdownstream heating element 25 toupstream heating element 1, and essentially no fentanyl was deposited on the downstream heating elements. - The purity and yield of emitted doses for devices as described in Example 1, except that the surface area of each support was 0.25 cm2, are presented in
FIGS. 20A and 20B .FIG. 20A shows that the purity of a 2.4 μm thick, 60 μg dose of fentanyl emitted from the device is greater than 98% when the peak temperature of the heating element is at least 375° C. As shown inFIG. 20B , at least 96% of the 2.4 μm thick, 60 μg dose of fentanyl disposed on a heating element was emitted from the device when heated to a temperature of at least 375° C. ForFIGS. 20A and 20B , the condensation aerosols comprising fentanyl were characterized by a MMAD of 2.0 μm and a GSD of 1.8 μm.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/388,881 US20170105246A1 (en) | 2004-06-03 | 2016-12-22 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/861,554 US7540286B2 (en) | 2004-06-03 | 2004-06-03 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US12/474,680 US8333197B2 (en) | 2004-06-03 | 2009-05-29 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US13/717,630 US20130180525A1 (en) | 2004-06-03 | 2012-12-17 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
US15/388,881 US20170105246A1 (en) | 2004-06-03 | 2016-12-22 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/717,630 Continuation US20130180525A1 (en) | 2004-06-03 | 2012-12-17 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170105246A1 true US20170105246A1 (en) | 2017-04-13 |
Family
ID=35446334
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/861,554 Active 2026-07-19 US7540286B2 (en) | 2004-06-03 | 2004-06-03 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US12/474,680 Active 2025-03-04 US8333197B2 (en) | 2004-06-03 | 2009-05-29 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US13/078,654 Abandoned US20110233043A1 (en) | 2004-06-03 | 2011-04-01 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US13/717,630 Abandoned US20130180525A1 (en) | 2004-06-03 | 2012-12-17 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
US15/388,881 Pending US20170105246A1 (en) | 2004-06-03 | 2016-12-22 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/861,554 Active 2026-07-19 US7540286B2 (en) | 2004-06-03 | 2004-06-03 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US12/474,680 Active 2025-03-04 US8333197B2 (en) | 2004-06-03 | 2009-05-29 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US13/078,654 Abandoned US20110233043A1 (en) | 2004-06-03 | 2011-04-01 | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US13/717,630 Abandoned US20130180525A1 (en) | 2004-06-03 | 2012-12-17 | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols |
Country Status (1)
Country | Link |
---|---|
US (5) | US7540286B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10166224B2 (en) | 2013-07-11 | 2019-01-01 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US10786635B2 (en) | 2010-08-26 | 2020-09-29 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
WO2021105476A1 (en) * | 2019-11-29 | 2021-06-03 | Nicoventures Trading Limited | Non-combustible aerosol provision device |
US11065400B2 (en) | 2001-06-05 | 2021-07-20 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11511054B2 (en) | 2015-03-11 | 2022-11-29 | Alexza Pharmaceuticals, Inc. | Use of antistatic materials in the airway for thermal aerosol condensation process |
US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
Families Citing this family (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
AU2003239433A1 (en) | 2002-05-13 | 2003-11-11 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
MXPA05005611A (en) | 2002-11-26 | 2005-07-27 | Alexza Pharmaceuticals Inc | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain. |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
ATE510174T1 (en) | 2003-05-21 | 2011-06-15 | Alexza Pharmaceuticals Inc | IMPACT LIT INDEPENDENT HEATING UNIT |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US9675109B2 (en) * | 2005-07-19 | 2017-06-13 | J. T. International Sa | Method and system for vaporization of a substance |
US11647783B2 (en) | 2005-07-19 | 2023-05-16 | Juul Labs, Inc. | Devices for vaporization of a substance |
US7537463B1 (en) | 2006-11-08 | 2009-05-26 | Tyco Electronics Corporation | Mechanically interconnected foil contact array and method of manufacturing |
US7987594B1 (en) | 2006-11-08 | 2011-08-02 | Tyco Electronics Corporation | Method of manufacturing an interconnected foil contact array |
US7481671B1 (en) | 2006-11-08 | 2009-01-27 | Tyco Electronics Coporation | Mechanically interconnected foil contact array having L-shaped contacts and method of making |
WO2008080170A1 (en) * | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
US7840122B1 (en) | 2007-01-19 | 2010-11-23 | IntriMed Technologies, Inc. | Medicine vaporizer with crimped conductive pins |
KR101221271B1 (en) * | 2007-11-29 | 2013-01-11 | 니뽄 다바코 산교 가부시키가이샤 | Aerosol inhaling apparatus |
CA2709071C (en) | 2007-12-14 | 2016-11-15 | Labogroup S.A.S. | Delivering aerosolizable food products |
US8991402B2 (en) | 2007-12-18 | 2015-03-31 | Pax Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
GB0802028D0 (en) † | 2008-02-05 | 2008-03-12 | Dunne Stephen T | Powder inhaler flow regulator |
US8418523B2 (en) | 2008-03-03 | 2013-04-16 | Keith Lueck | Calibration and accuracy check system for a breath tester |
US8201752B2 (en) * | 2008-03-10 | 2012-06-19 | Vapore, Inc. | Low energy vaporization of liquids: apparatus and methods |
EP2100525A1 (en) * | 2008-03-14 | 2009-09-16 | Philip Morris Products S.A. | Electrically heated aerosol generating system and method |
EP2113178A1 (en) * | 2008-04-30 | 2009-11-04 | Philip Morris Products S.A. | An electrically heated smoking system having a liquid storage portion |
US7845277B2 (en) * | 2008-05-28 | 2010-12-07 | Autoliv Asp, Inc. | Header assembly |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100065052A1 (en) * | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
AT507187B1 (en) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | INHALER |
EP2198972A1 (en) | 2008-12-18 | 2010-06-23 | Boehringer Ingelheim International GmbH | Reservoir and atomiser |
US8905017B2 (en) | 2009-03-17 | 2014-12-09 | Boehringer Ingelheim International Gmbh | Reservoir and atomizer |
EP2425224A1 (en) | 2009-04-28 | 2012-03-07 | Boehringer Ingelheim International GmbH | Method for checking the tightness of a container filled with a fluid |
US20100300433A1 (en) * | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US20110094524A1 (en) * | 2009-10-27 | 2011-04-28 | Glover Darrell F | Smoking Apparatus Having Diffuser |
EP2319334A1 (en) | 2009-10-27 | 2011-05-11 | Philip Morris Products S.A. | A smoking system having a liquid storage portion |
EP2316286A1 (en) | 2009-10-29 | 2011-05-04 | Philip Morris Products S.A. | An electrically heated smoking system with improved heater |
AT509046B1 (en) | 2010-03-10 | 2011-06-15 | Helmut Dr Buchberger | FLAT EVAPORATOR |
WO2011124033A1 (en) * | 2010-04-09 | 2011-10-13 | Liu Qiuming | Electronic cigarette atomization device |
CN103068425A (en) * | 2010-06-28 | 2013-04-24 | 帕利亚技术公司 | Vaporizable substance drug delivery and monitoring system |
EP2608829A4 (en) | 2010-08-23 | 2015-11-18 | Darren Rubin | Systems and methods of aerosol delivery with airflow regulation |
US11247003B2 (en) | 2010-08-23 | 2022-02-15 | Darren Rubin | Systems and methods of aerosol delivery with airflow regulation |
US9757528B2 (en) | 2010-08-23 | 2017-09-12 | Darren Rubin | Nebulizer having different negative pressure threshold settings |
US9301547B2 (en) * | 2010-11-19 | 2016-04-05 | Huizhou Kimree Technology Co., Ltd. Shenzhen Branch | Electronic cigarette, electronic cigarette smoke capsule and atomization device thereof |
EP2654864B1 (en) | 2010-12-22 | 2020-10-28 | Syqe Medical Ltd. | System for drug delivery |
AT510837B1 (en) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | INHALATORKOMPONENTE |
US8752545B2 (en) | 2011-02-11 | 2014-06-17 | Batmark Limited | Inhaler component |
CA2845090C (en) | 2011-08-16 | 2023-01-31 | Ploom, Inc. | Low temperature electronic vaporization device and methods |
JP2014518095A (en) | 2011-09-06 | 2014-07-28 | ブリティッシュ アメリカン タバコ (インヴェストメンツ) リミテッド | Smoking material heating |
JP5879435B2 (en) | 2011-09-06 | 2016-03-08 | ブリティッシュ アメリカン タバコ (インヴェストメンツ) リミテッドBritish Americantobacco (Investments) Limited | Smoking material heating |
HUE053875T2 (en) | 2011-09-06 | 2021-07-28 | Nicoventures Trading Ltd | Heating smokable material |
CN103763953B (en) | 2011-09-06 | 2016-08-17 | 英美烟草(投资)有限公司 | Heating smokeable material |
GB201207054D0 (en) | 2011-09-06 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
AT511344B1 (en) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | INHALATORKOMPONENTE |
US9282772B2 (en) | 2012-01-31 | 2016-03-15 | Altria Client Services Llc | Electronic vaping device |
GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
GB2502055A (en) * | 2012-05-14 | 2013-11-20 | Nicoventures Holdings Ltd | Modular electronic smoking device |
GB2502053B (en) * | 2012-05-14 | 2014-09-24 | Nicoventures Holdings Ltd | Electronic smoking device |
GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
AU2012388598B2 (en) * | 2012-08-31 | 2016-11-24 | Huizhou Kimree Technology Co., Ltd., Shenzhen Branch | Electronic cigarette |
GB201217067D0 (en) | 2012-09-25 | 2012-11-07 | British American Tobacco Co | Heating smokable material |
GB2507103A (en) | 2012-10-19 | 2014-04-23 | Nicoventures Holdings Ltd | Electronic inhalation device |
GB2507104A (en) * | 2012-10-19 | 2014-04-23 | Nicoventures Holdings Ltd | Electronic inhalation device |
US10034988B2 (en) | 2012-11-28 | 2018-07-31 | Fontem Holdings I B.V. | Methods and devices for compound delivery |
AU2013352141B2 (en) | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
US20140261488A1 (en) * | 2013-03-15 | 2014-09-18 | Altria Client Services Inc. | Electronic smoking article |
US9884157B2 (en) * | 2013-03-15 | 2018-02-06 | Microdose Therapeutx, Inc. | Inhalation device, control method and computer program |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2513638A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
MX2015015175A (en) | 2013-05-06 | 2016-01-12 | Pax Labs Inc | Nicotine salt formulations for aerosol devices and methods thereof. |
GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
WO2014201432A1 (en) | 2013-06-14 | 2014-12-18 | Ploom, Inc. | Multiple heating elements with separate vaporizable materials in an electric vaporization device |
GB201311620D0 (en) | 2013-06-28 | 2013-08-14 | British American Tobacco Co | Devices Comprising a Heat Source Material and Activation Chambers for the Same |
EP4179891A1 (en) | 2013-08-06 | 2023-05-17 | Fontem Ventures B.V. | Electronic smoking device and process of manufacturing thereof |
GB2518598B (en) | 2013-08-30 | 2016-06-01 | Nicoventures Holdings Ltd | Apparatus with battery power control |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
US9992995B2 (en) | 2013-09-25 | 2018-06-12 | Agrofresh Inc. | Systems and methods for solvent-free delivery of volatile compounds |
GB2519101A (en) | 2013-10-09 | 2015-04-15 | Nicoventures Holdings Ltd | Electronic vapour provision system |
EP3685690B1 (en) | 2013-10-29 | 2022-05-04 | Nicoventures Trading Limited | Apparatus for heating smokable material |
GB2522727B (en) * | 2013-11-26 | 2017-01-25 | Purity Health Pharma Ltd | Pulmonary delivery devices |
EP3076805A4 (en) | 2013-12-05 | 2017-10-11 | PAX Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US9549573B2 (en) | 2013-12-23 | 2017-01-24 | Pax Labs, Inc. | Vaporization device systems and methods |
HUE053216T2 (en) | 2013-12-23 | 2021-06-28 | Juul Labs Int Inc | Vaporization device systems |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
CN111418895B (en) | 2014-02-10 | 2023-09-08 | 菲利普莫里斯生产公司 | Aerosol generating system and cartridge for an aerosol generating system |
CA2937976C (en) * | 2014-02-10 | 2023-04-04 | Philip Morris Products S.A. | An aerosol-generating system having a fluid-permeable heater assembly |
US10821240B2 (en) * | 2014-02-11 | 2020-11-03 | Vapor Cartridge Technology Llc | Methods and drug delivery devices using cannabis |
US9220294B2 (en) | 2014-02-11 | 2015-12-29 | Timothy McCullough | Methods and devices using cannabis vapors |
US9380813B2 (en) | 2014-02-11 | 2016-07-05 | Timothy McCullough | Drug delivery system and method |
US9597466B2 (en) * | 2014-03-12 | 2017-03-21 | R. J. Reynolds Tobacco Company | Aerosol delivery system and related method, apparatus, and computer program product for providing control information to an aerosol delivery device via a cartridge |
PL3119218T3 (en) * | 2014-03-19 | 2020-05-18 | Philip Morris Products S.A. | Monolithic plane with electrical contacts and methods for manufacturing the same |
US9726653B2 (en) * | 2014-03-26 | 2017-08-08 | Hamilton Sundstrand Corporation | Chemical detector |
GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
US11478021B2 (en) | 2014-05-16 | 2022-10-25 | Juul Labs, Inc. | Systems and methods for aerosolizing a vaporizable material |
GB201500582D0 (en) | 2015-01-14 | 2015-02-25 | British American Tobacco Co | Apparatus for heating or cooling a material contained therein |
GB201411483D0 (en) | 2014-06-27 | 2014-08-13 | Batmark Ltd | Vaporizer Assembly |
WO2016001921A2 (en) * | 2014-06-30 | 2016-01-07 | Syqe Medical Ltd. | Method and device for vaporization and inhalation of isolated substances |
US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
CA2953073A1 (en) | 2014-06-30 | 2016-01-07 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
ES2898173T3 (en) | 2014-06-30 | 2022-03-04 | Syqe Medical Ltd | Devices and systems for the pulmonary administration of active ingredients |
IL285111B (en) | 2014-06-30 | 2022-07-01 | Syqe Medical Ltd | Flow regulating inhaler device |
EP3939639A1 (en) | 2014-06-30 | 2022-01-19 | Syqe Medical Ltd. | Drug dose cartridge for an inhaler device |
AU2015283590B2 (en) | 2014-06-30 | 2020-04-16 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
CA160775S (en) | 2014-08-11 | 2015-09-29 | Ploom Inc | Electronic vaporization device with cartridge |
GB2529201A (en) | 2014-08-13 | 2016-02-17 | Batmark Ltd | Device and method |
US9913493B2 (en) | 2014-08-21 | 2018-03-13 | Rai Strategic Holdings, Inc. | Aerosol delivery device including a moveable cartridge and related assembly method |
US10765144B2 (en) | 2014-08-21 | 2020-09-08 | Rai Strategic Holdings, Inc. | Aerosol delivery device including a moveable cartridge and related assembly method |
US10898660B2 (en) * | 2014-09-10 | 2021-01-26 | Fontem Holdings 1 B.V. | Methods and devices for modulating air flow in delivery devices |
UA124185C2 (en) | 2014-12-05 | 2021-08-04 | Джуул Лебз, Інк. | Calibrated dose control |
GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
GB201423318D0 (en) | 2014-12-29 | 2015-02-11 | British American Tobacco Co | Cartridge for use with apparatus for heating smokable material |
GB201423317D0 (en) | 2014-12-29 | 2015-02-11 | British American Tobacco Co | Apparatus for heating smokable material |
GB201423312D0 (en) | 2014-12-29 | 2015-02-11 | British American Tobacco Co | Heating device for apparatus for heating smokable material and method of manufacture |
PL3247235T3 (en) | 2015-01-22 | 2021-04-06 | Fontem Holdings 1 B.V. | Electronic vaporization devices |
CN107750129B (en) | 2015-04-22 | 2020-09-25 | 奥驰亚客户服务有限责任公司 | Pod assembly, dispensing body and electronic cigarette device including same |
USD980507S1 (en) | 2015-04-22 | 2023-03-07 | Altria Client Services Llc | Electronic vaping device |
US10701981B2 (en) | 2015-04-22 | 2020-07-07 | Altria Client Services Llc | Pod assembly and e-vapor apparatus including the same |
EP3285844B1 (en) * | 2015-04-22 | 2019-07-17 | Altria Client Services LLC | Pod assembly, dispensing body, and e-vapor apparatus including the same |
US9999258B2 (en) | 2015-04-22 | 2018-06-19 | Altria Client Services Llc | Pod assembly, dispensing body, and e-vapor apparatus including the same |
US10104913B2 (en) | 2015-04-22 | 2018-10-23 | Altria Client Services Llc | Pod assembly, dispensing body, and E-vapor apparatus including the same |
US10064432B2 (en) * | 2015-04-22 | 2018-09-04 | Altria Client Services Llc | Pod assembly, dispensing body, and E-vapor apparatus including the same |
USD874720S1 (en) | 2015-04-22 | 2020-02-04 | Altria Client Services, Llc | Pod for an electronic vaping device |
USD874059S1 (en) | 2015-04-22 | 2020-01-28 | Altria Client Servies Llc | Electronic vaping device |
US20170030882A1 (en) * | 2015-05-01 | 2017-02-02 | Ahkeo Ventures LLC | Systems and methods for dipstick diagnostic tools and related methods |
SE539111C2 (en) * | 2015-06-03 | 2017-04-11 | Iconovo Ab | Single dose dry powder inhaler |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
GB2540135B (en) | 2015-07-01 | 2021-03-03 | Nicoventures Holdings Ltd | Electronic aerosol provision system |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US20170055575A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Material for use with apparatus for heating smokable material |
GB201517089D0 (en) | 2015-09-28 | 2015-11-11 | Nicoventures Holdings Ltd | Vaping heat map system and method for electronic vapour provision systems |
US10058125B2 (en) | 2015-10-13 | 2018-08-28 | Rai Strategic Holdings, Inc. | Method for assembling an aerosol delivery device |
US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
US20170119047A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Article for Use with Apparatus for Heating Smokable Material |
CN205321204U (en) * | 2015-11-06 | 2016-06-22 | 昂纳自动化技术(深圳)有限公司 | Temperature control system of electron cigarette |
US10092036B2 (en) * | 2015-12-28 | 2018-10-09 | Rai Strategic Holdings, Inc. | Aerosol delivery device including a housing and a coupler |
CA3009599A1 (en) | 2016-01-06 | 2017-07-13 | Syqe Medical Ltd. | Low dose therapeutic treatment |
EP4298937A3 (en) | 2016-01-11 | 2024-04-10 | Syqe Medical Ltd. | Personal vaporizing device |
USD861975S1 (en) | 2016-02-08 | 2019-10-01 | Juul Labs, Inc. | Vaporizer device with cartridges |
SG11201806793TA (en) | 2016-02-11 | 2018-09-27 | Juul Labs Inc | Fillable vaporizer cartridge and method of filling |
MX2018009703A (en) | 2016-02-11 | 2019-07-08 | Juul Labs Inc | Securely attaching cartridges for vaporizer devices. |
US10433580B2 (en) | 2016-03-03 | 2019-10-08 | Altria Client Services Llc | Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge |
US10455863B2 (en) | 2016-03-03 | 2019-10-29 | Altria Client Services Llc | Cartridge for electronic vaping device |
US10368580B2 (en) * | 2016-03-08 | 2019-08-06 | Altria Client Services Llc | Combined cartridge for electronic vaping device |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US10357060B2 (en) | 2016-03-11 | 2019-07-23 | Altria Client Services Llc | E-vaping device cartridge holder |
US10368581B2 (en) | 2016-03-11 | 2019-08-06 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
JP2019520787A (en) | 2016-04-27 | 2019-07-25 | ニコベンチャーズ ホールディングス リミテッド | Electronic aerosol supply system and vaporizer for electronic aerosol supply system |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
US9993025B2 (en) * | 2016-07-25 | 2018-06-12 | Fontem Holdings 1 B.V. | Refillable electronic cigarette clearomizer |
GB201612945D0 (en) | 2016-07-26 | 2016-09-07 | British American Tobacco Investments Ltd | Method of generating aerosol |
US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
CA3041308A1 (en) * | 2016-10-21 | 2018-04-26 | Somniferum Labs LLC | Method, system and apparatus for controlled delivery of opioid and other medications |
US10834967B2 (en) | 2016-12-27 | 2020-11-17 | Gofire, Inc. | System and method for managing concentrate usage of a user |
EP3562342A1 (en) * | 2016-12-30 | 2019-11-06 | JT International S.A. | Electrically operated aerosol generation system |
JP2020503894A (en) | 2016-12-30 | 2020-02-06 | ジェイ・ティ・インターナショナル・ソシエテ・アノニムJt International S.A. | Electric aerosol generation system |
US20180338905A1 (en) * | 2017-05-26 | 2018-11-29 | Inhale Health, LLC | Bioavailable aerosolized supplement formulations |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
GB201721821D0 (en) | 2017-12-22 | 2018-02-07 | Nicoventures Holdings Ltd | Electronic aerosol provision system |
RU2765175C1 (en) * | 2018-06-14 | 2022-01-26 | Филип Моррис Продактс С.А. | Aerosol generating device with flat heater |
US11464082B2 (en) * | 2018-07-31 | 2022-10-04 | Juul Labs, Inc. | Cartridge-based heat not burn vaporizer |
KR20210089138A (en) * | 2018-11-13 | 2021-07-15 | 필립모리스 프로덕츠 에스.에이. | heater array |
WO2020104377A1 (en) * | 2018-11-22 | 2020-05-28 | Smokeless.World Gmbh | E-cigarette with authentication for nicotine delivery |
US10888666B2 (en) | 2019-01-02 | 2021-01-12 | Gofire, Inc. | System and method for multi-modal dosing device |
US11607506B2 (en) | 2019-02-22 | 2023-03-21 | Altria Client Services Llc | Electronic dispersion device |
US20220168518A1 (en) * | 2019-02-27 | 2022-06-02 | NuvoAir AB | A method and a device for estimating an amount of a powder shaped material passing a bend in a flow channel |
GB201903248D0 (en) * | 2019-03-11 | 2019-04-24 | Nicoventures Trading Ltd | Aerosol provision device |
US11497249B2 (en) | 2019-09-16 | 2022-11-15 | Vapor Cartridge Technology Llc | Drug delivery system with stackable substrates |
EP3794986A1 (en) * | 2019-09-20 | 2021-03-24 | Nerudia Limited | Smoking substitute apparatus |
USD943159S1 (en) | 2019-11-14 | 2022-02-08 | Juul Labs, Inc. | Component for a vaporizer cartridge |
USD943160S1 (en) | 2019-11-14 | 2022-02-08 | Juul Labs, Inc. | Vaporizer device |
USD943161S1 (en) | 2019-11-14 | 2022-02-08 | Juul Labs, Inc. | Vaporizer device |
USD943158S1 (en) | 2019-11-14 | 2022-02-08 | Juul Labs, Inc. | Vaporizer cartridge |
US20210299288A1 (en) * | 2020-03-25 | 2021-09-30 | Jackson Alexander Townsend | Apparatuses and methods to attenuate viruses |
US11109622B1 (en) | 2020-03-30 | 2021-09-07 | Gofire, Inc. | System and method for metered dosing vaporizer |
JP1714442S (en) | 2020-10-30 | 2022-05-10 | Smoking aerosol generator | |
JP1715888S (en) | 2020-10-30 | 2022-05-25 | Smoking aerosol generator | |
JP1714440S (en) | 2020-10-30 | 2022-05-10 | Smoking aerosol generator | |
JP1714443S (en) | 2020-10-30 | 2022-05-10 | Smoking aerosol generator | |
JP1714441S (en) | 2020-10-30 | 2022-05-10 | Smoking aerosol generator | |
USD990765S1 (en) | 2020-10-30 | 2023-06-27 | Nicoventures Trading Limited | Aerosol generator |
USD989384S1 (en) | 2021-04-30 | 2023-06-13 | Nicoventures Trading Limited | Aerosol generator |
CN113842527B (en) * | 2021-08-27 | 2023-08-15 | 兆科药业(广州)有限公司 | Drug inhalation device and supervision system |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5586550A (en) * | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US6554201B2 (en) * | 2001-05-02 | 2003-04-29 | Aerogen, Inc. | Insert molded aerosol generator and methods |
US20050051165A1 (en) * | 2003-09-04 | 2005-03-10 | Cole Maury D. | Substance inhalation system |
US8387612B2 (en) * | 2003-05-21 | 2013-03-05 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
Family Cites Families (452)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2243669A (en) | 1941-05-27 | Electrical vaporizer | ||
US1803334A (en) | 1931-05-05 | Ootthujp lehmann | ||
US3080624A (en) | 1963-03-12 | weber iii | ||
US1864980A (en) | 1932-06-28 | Vapobizeb | ||
US1239634A (en) | 1916-07-25 | 1917-09-11 | Frank J Stuart | Medical appliance. |
US1535486A (en) | 1922-08-28 | 1925-04-28 | James W Lundy | Electric-lamp bulb |
US2086140A (en) | 1933-09-08 | 1937-07-06 | Silten Ernst | Automatic temperature regulated narcosis apparatus |
US2084299A (en) | 1934-12-15 | 1937-06-15 | Arthur G Borden | Medicament holder for nasal inhalers |
US2230753A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
US2230754A (en) | 1937-02-15 | 1941-02-04 | Bilhuber Corp E | Unsaturated ethylamine derivatives |
GB502761A (en) | 1938-01-29 | 1939-03-24 | Christopher Engelbreth | Improvements in and relating to hand inhalation apparatus |
US2309846A (en) | 1941-03-06 | 1943-02-02 | Holm Einar Marius | Inhaler |
FR921852A (en) | 1945-12-06 | 1947-05-21 | Diffuser of volatile products | |
US2469656A (en) | 1946-04-19 | 1949-05-10 | Peter H Lienert | Vaporizer |
US2714649A (en) | 1952-11-25 | 1955-08-02 | Lyle H Critzer | Vaporizer |
US2761055A (en) | 1953-06-10 | 1956-08-28 | Malcome Van Ike | Lamp-heated vaporizer |
US2741812A (en) | 1954-02-15 | 1956-04-17 | Tellier Andre | Perfume dispenser |
US2902484A (en) | 1954-04-27 | 1959-09-01 | Rhone Poulenc Sa | Phenthiazine derivatives and processes for their preparation |
US2887106A (en) | 1956-09-27 | 1959-05-19 | Robinson Joseph | Combined vaporizer and cover for medicament jar |
US2898649A (en) | 1956-11-19 | 1959-08-11 | Elaine T Cassidy | Perfume diffuser |
US3371085A (en) | 1959-12-10 | 1968-02-27 | Hoffmann La Roche | 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones |
US3043977A (en) | 1960-03-30 | 1962-07-10 | Puritron Corp | Device and method for producing negative ions |
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
GB903866A (en) | 1961-05-09 | 1962-08-22 | Dausse Lab | Therapeutic preparations containing 7-substituted theophylline derivatives |
BE623427A (en) | 1961-10-10 | |||
US3299185A (en) | 1962-09-27 | 1967-01-17 | Ube Nitto Kasei Co | Dyeable polyolefin fibers containing a binary copolymer of styrene and acrylonitrile |
US3169095A (en) | 1962-10-30 | 1965-02-09 | Rexall Drug Chemical | Self-propelling powder-dispensing compositions |
NL289785A (en) | 1962-11-29 | |||
GB1063512A (en) | 1962-11-30 | 1967-03-30 | Benger Lab Ltd | Aerosols |
US3282729A (en) | 1963-02-27 | 1966-11-01 | Union Carbide Corp | Barrier coated thermoplastic olefin polymer substrates |
US3200819A (en) | 1963-04-17 | 1965-08-17 | Herbert A Gilbert | Smokeless non-tobacco cigarette |
NL298071A (en) | 1963-06-04 | |||
IL26896A (en) | 1966-01-19 | 1970-11-30 | Endo Lab | 14-hydroxynormorphines and 14-hydroxynormorphinones |
US3909463A (en) | 1968-11-29 | 1975-09-30 | Allied Chem | Grafted block copolymers of synthetic rubbers and polyolefins |
US3987052A (en) | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
US4008723A (en) | 1970-03-23 | 1977-02-22 | Imperial Chemical Industries Limited | Smoking mixture |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3831606A (en) | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
US3749547A (en) | 1971-09-09 | 1973-07-31 | Airco Inc | Flashlamp with improved combustible foil |
US3847650A (en) | 1971-09-09 | 1974-11-12 | Airco Inc | Flashlamp with improved combustion foil and method of making same |
US4166087A (en) | 1971-11-22 | 1979-08-28 | Cline-Buckner, Inc. | Automatic intermittent vapor dispenser |
US3701782A (en) | 1972-02-10 | 1972-10-31 | Upjohn Co | 1-carbolower alkoxy - 6 - phenyl-4h-s-triazolo(1,4)benzodiazepine compounds |
US3763347A (en) | 1972-04-13 | 1973-10-02 | Ncr Co | Vaporous lamp |
IE37524B1 (en) | 1972-04-20 | 1977-08-17 | Gallaher Ltd | Synthetic smoking product |
US3864326A (en) | 1972-05-22 | 1975-02-04 | Robert S Babington | Spraying devices, in particular nebulizing devices |
USRE30285E (en) | 1972-05-22 | 1980-05-27 | Spraying devices, in particular nebulizing devices | |
GB1366041A (en) | 1972-07-21 | 1974-09-11 | Kodama Bros Co Ltd | Device for volatilizing insecticides and the like |
US3773995A (en) | 1972-10-27 | 1973-11-20 | Westinghouse Electric Corp | Motor advanced spring charging pawl and ratchet mechanism with spring assist |
US3949743A (en) | 1973-03-19 | 1976-04-13 | Schick Incorporated | Medicated vapor production method and apparatus |
US3930796A (en) | 1973-09-13 | 1976-01-06 | Universal Oil Products Company | Catalytic fume control device |
US3982095A (en) | 1973-10-04 | 1976-09-21 | Searle Cardio-Pulmonary Systems Inc. | Respiratory humidifier |
US3971377A (en) | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
US3894040A (en) | 1974-09-16 | 1975-07-08 | American Home Prod | 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters |
US4045156A (en) | 1974-12-23 | 1977-08-30 | Gte Sylvania Incorporated | Photoflash lamp |
US4020379A (en) | 1975-10-02 | 1977-04-26 | Eg&G, Inc. | Bulb-shaped flashtube with metal envelope |
US4104210A (en) | 1975-12-17 | 1978-08-01 | Monsanto Company | Thermoplastic compositions of high unsaturation diene rubber and polyolefin resin |
US4121583A (en) | 1976-07-13 | 1978-10-24 | Wen Yuan Chen | Method and apparatus for alleviating asthma attacks |
US4286604A (en) | 1976-10-05 | 1981-09-01 | Gallaher Limited | Smoking materials |
US4079742A (en) | 1976-10-20 | 1978-03-21 | Philip Morris Incorporated | Process for the manufacture of synthetic smoking materials |
US4160765A (en) | 1976-11-17 | 1979-07-10 | Smithkline Corporation | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
US4141369A (en) | 1977-01-24 | 1979-02-27 | Burruss Robert P | Noncombustion system for the utilization of tobacco and other smoking materials |
US4184099A (en) | 1977-04-27 | 1980-01-15 | International Flavors & Fragrances Inc. | Composition for slow release of volatile ingredients at _high temperature; and article comprising same |
DE2752384A1 (en) | 1977-08-29 | 1979-03-15 | Simes | PHARMACEUTICAL PREPARATION BASED ON ANTY-RELEASE AGENTS AND INHIBITANTS OF BETA ADRENERGIC RECEPTORS |
SE7812207L (en) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES |
US4183912A (en) | 1978-01-16 | 1980-01-15 | American Home Products Corporation | Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine |
JPS54120065A (en) | 1978-02-24 | 1979-09-18 | Osaka Takeshi | Stick for blind person |
US4198200A (en) | 1978-05-18 | 1980-04-15 | Lord Corporation | Damage-preventive coatings |
US4284089A (en) | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
US4276243A (en) | 1978-12-08 | 1981-06-30 | Western Electric Company, Inc. | Vapor delivery control system and method |
US4280629A (en) | 1979-01-08 | 1981-07-28 | Anchor Brush Company, Inc. | Container for nail polish or the like |
US4219031A (en) | 1979-03-05 | 1980-08-26 | Philip Morris Incorporated | Smoking product having core of fibrillar carbonized matter |
US4229931A (en) | 1979-03-05 | 1980-10-28 | Deere & Company | Hydraulic height sensing system with cylinder by-pass |
IL59407A (en) | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
US4251525A (en) | 1979-05-25 | 1981-02-17 | Smithkline Corporation | 3-Allyl-7,8-dihydroxy-6-halo-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
GB2064296B (en) | 1979-11-16 | 1983-06-22 | Imp Group Ltd | Cigarette or cigarette-like device which produces aerosol in smoke |
EP0039369B1 (en) | 1980-05-02 | 1983-06-15 | Schering Corporation | Beclomethasone ester solvates, process for their preparation, and preparation of a formulation |
US4391285A (en) | 1980-05-09 | 1983-07-05 | Philip Morris, Incorporated | Smoking article |
US4347855A (en) | 1980-07-23 | 1982-09-07 | Philip Morris Incorporated | Method of making smoking articles |
US4303083A (en) | 1980-10-10 | 1981-12-01 | Burruss Jr Robert P | Device for evaporation and inhalation of volatile compounds and medications |
US4376767A (en) | 1981-01-02 | 1983-03-15 | Merck & Co., Inc. | Pyridylmethyl esters of selected bio-affecting carboxylic acids |
US4346059A (en) | 1981-03-03 | 1982-08-24 | Donald Spector | Aroma-generating lamp structure |
DE3116951C2 (en) | 1981-04-29 | 1984-12-20 | Drägerwerk AG, 2400 Lübeck | Device for adding liquid anesthetics to the breathing gas to be supplied to the patient |
JPS5876038A (en) | 1981-10-28 | 1983-05-09 | 高森 正之 | Evaporation apparatus of insecticide or aromatic agent |
GB2122903B (en) | 1982-06-22 | 1986-11-05 | Masayuki Takamori | Vaporizers for vaporisable substances and support media for substances usable therewith |
DE3224849A1 (en) | 1982-07-02 | 1984-01-05 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | STEAM INHALER |
US4556539A (en) | 1982-08-27 | 1985-12-03 | Donald Spector | Disc-playing aroma generator |
US4508726A (en) | 1982-09-16 | 1985-04-02 | The Upjohn Company | Treatment of panic disorders with alprazolam |
NL8320301A (en) | 1982-09-30 | 1984-08-01 | Dainippon Jochugiku Kk | THERMAL EVAPORATING DEVICE FOR CHEMICAL SUBSTANCES. |
US4474191A (en) | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
US4753758A (en) | 1983-05-19 | 1988-06-28 | Intertech Resources Inc. | Respiratory humidifier |
DE3320441A1 (en) * | 1983-06-06 | 1984-12-06 | Siemens AG, 1000 Berlin und 8000 München | WRITING DEVICE WORKING WITH LIQUID DROPLETS WITH ROD-SHAPED PIEZOELECTRIC TRANSFORMERS CONNECTED ON BOTH ENDS WITH A NOZZLE PLATE |
US4523589A (en) | 1983-06-29 | 1985-06-18 | Krauser Robert S | Method and apparatus for treating ailments |
US5038769A (en) | 1983-06-29 | 1991-08-13 | Krauser Robert S | Method and apparatus for treating ailments |
DE3326089A1 (en) | 1983-07-20 | 1985-02-07 | Gödecke AG, 1000 Berlin | INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS |
US4588721A (en) | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
DE3478900D1 (en) | 1983-11-08 | 1989-08-17 | Bunnell Life Systems Inc | Humidifier, particularly for pulmonary assistance systems |
GB8405190D0 (en) | 1984-02-28 | 1984-04-04 | British Petroleum Co Plc | Thermoplastic elastomer composition |
US4627963A (en) | 1984-02-29 | 1986-12-09 | Lad Technology, Inc. | Heat activated dispenser and method of dispensing a vapor therefrom |
US4683231A (en) | 1984-03-02 | 1987-07-28 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4647428A (en) | 1984-06-04 | 1987-03-03 | Gyulay Joseph M | Air freshener method |
US4755508A (en) | 1984-06-26 | 1988-07-05 | Merck & Co., Inc. | Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin |
US4793365A (en) | 1984-09-14 | 1988-12-27 | R. J. Reynolds Tobacco Company | Smoking article |
US5020548A (en) | 1985-08-26 | 1991-06-04 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US4854331A (en) | 1984-09-14 | 1989-08-08 | R. J. Reynolds Tobacco Company | Smoking article |
US5042509A (en) | 1984-09-14 | 1991-08-27 | R. J. Reynolds Tobacco Company | Method for making aerosol generating cartridge |
US5067499A (en) | 1984-09-14 | 1991-11-26 | R. J. Reynolds Tobacco Company | Smoking article |
US4647433A (en) | 1984-10-01 | 1987-03-03 | Donald Spector | Long-life aroma-generating capsule |
CN1018607B (en) | 1984-12-21 | 1992-10-14 | 美国耳·杰·瑞诺兹烟草公司 | Smoking article |
GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
US4928714A (en) | 1985-04-15 | 1990-05-29 | R. J. Reynolds Tobacco Company | Smoking article with embedded substrate |
US5119834A (en) | 1985-04-15 | 1992-06-09 | R. J. Reynolds Tobacco Company | Smoking article with improved substrate |
JPS63500175A (en) * | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−,インコ−ポレイテツド | Liposome inhalation method and inhalation system |
US4800903A (en) * | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
US4722334A (en) | 1985-07-16 | 1988-02-02 | Transpirator Technologies, Inc. | Method and apparatus for pulmonary and cardiovascular conditioning of racehorses and competition animals |
US4989619A (en) * | 1985-08-26 | 1991-02-05 | R. J. Reynolds Tobacco Company | Smoking article with improved fuel element |
US5105831A (en) | 1985-10-23 | 1992-04-21 | R. J. Reynolds Tobacco Company | Smoking article with conductive aerosol chamber |
US5033483A (en) | 1985-10-28 | 1991-07-23 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US5060666A (en) | 1985-10-28 | 1991-10-29 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US4793366A (en) | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
JPS62204756A (en) | 1986-03-04 | 1987-09-09 | 大研医工株式会社 | Drug volatilizing method and apparatus |
DE3767615D1 (en) | 1986-03-10 | 1991-02-28 | Kurt Burghart | PHARMACEUTICAL AND METHOD FOR THE PRODUCTION THEREOF. |
US4708151A (en) | 1986-03-14 | 1987-11-24 | R. J. Reynolds Tobacco Company | Pipe with replaceable cartridge |
US4765347A (en) | 1986-05-09 | 1988-08-23 | R. J. Reynolds Tobacco Company | Aerosol flavor delivery system |
US4771795A (en) | 1986-05-15 | 1988-09-20 | R. J. Reynolds Tobacco Company | Smoking article with dual burn rate fuel element |
US4917120A (en) | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
US4774971A (en) | 1986-06-03 | 1988-10-04 | Vieten Michael J | Cigarette substitute |
US4801411A (en) * | 1986-06-05 | 1989-01-31 | Southwest Research Institute | Method and apparatus for producing monosize ceramic particles |
US4735217A (en) | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
US4858630A (en) | 1986-12-08 | 1989-08-22 | R. J. Reynolds Tobacco Company | Smoking article with improved aerosol forming substrate |
IL84516A0 (en) | 1986-12-12 | 1988-04-29 | Reynolds Tobacco Co R | Smoking articles comprising impact modifying agents |
US4734560A (en) | 1987-01-20 | 1988-03-29 | Medical Enterprises, Ltd. | Vaporizing unit |
US4819665A (en) | 1987-01-23 | 1989-04-11 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US4968885A (en) | 1987-03-06 | 1990-11-06 | Extrel Corporation | Method and apparatus for introduction of liquid effluent into mass spectrometer and other gas-phase or particle detectors |
US4924883A (en) | 1987-03-06 | 1990-05-15 | R. J. Reynolds Tobacco Company | Smoking article |
US4889850A (en) | 1987-05-11 | 1989-12-26 | Thornfeldt Carl R | Treatment of colic and teething |
US5017575A (en) | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
GB8713645D0 (en) | 1987-06-11 | 1987-07-15 | Imp Tobacco Ltd | Smoking device |
US5019122A (en) | 1987-08-21 | 1991-05-28 | R. J. Reynolds Tobacco Company | Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance |
US4935624A (en) | 1987-09-30 | 1990-06-19 | Cornell Research Foundation, Inc. | Thermal-assisted electrospray interface (TAESI) for LC/MS |
US5072726A (en) | 1987-10-09 | 1991-12-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Vaporizer for inhalation anesthetics during high-frequency jet ventilation and associated method |
US4911157A (en) * | 1988-01-07 | 1990-03-27 | Pegasus Research Corporation | Self-regulating, heated nebulizer system |
US4906417A (en) * | 1988-02-08 | 1990-03-06 | Associated Mills Inc. | Humidifier |
JPH01221313A (en) | 1988-02-29 | 1989-09-04 | Hayashi Teruaki | Sublimation-releasable medicine composition and releasing system thereof |
US4853517A (en) | 1988-03-28 | 1989-08-01 | John G. Bowen | Vaporizing unit |
DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
US5137034A (en) | 1988-05-16 | 1992-08-11 | R. J. Reynolds Tobacco Company | Smoking article with improved means for delivering flavorants |
US4881556A (en) | 1988-06-06 | 1989-11-21 | R. J. Reynolds Tobacco Company | Low CO smoking article |
US5264433A (en) | 1988-07-07 | 1993-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
CH678151A5 (en) | 1988-07-13 | 1991-08-15 | Heinz Hermann Weick | Self-medication nasal dispenser |
US5345951A (en) | 1988-07-22 | 1994-09-13 | Philip Morris Incorporated | Smoking article |
US4852561A (en) | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
US4947875A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Flavor delivery articles utilizing electrical energy |
US4947874A (en) | 1988-09-08 | 1990-08-14 | R. J. Reynolds Tobacco Company | Smoking articles utilizing electrical energy |
EP0358114A3 (en) | 1988-09-08 | 1990-11-14 | R.J. Reynolds Tobacco Company | Aerosol delivery articles utilizing electrical energy |
US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
USRE36744E (en) | 1988-09-16 | 2000-06-20 | Ribogene, Inc. | Nasal administration of benzodiazepine hypnotics |
US4917830A (en) | 1988-09-19 | 1990-04-17 | The United States Of America As Represented By The United States Department Of Energy | Monodisperse aerosol generator |
US4963289A (en) | 1988-09-19 | 1990-10-16 | The United States Of America As Represented By The United States Department Of Energy | Method for producing monodisperse aerosols |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
HU200105B (en) | 1988-10-04 | 1990-04-28 | Ferenc Inkovics | Electrically actuated inhaler of uniform medicine feeding |
US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US4917119A (en) | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US4959380A (en) | 1988-12-19 | 1990-09-25 | Wilson Jordan E | Method of treating people to stop smoking and composition |
US4881541A (en) | 1988-12-21 | 1989-11-21 | The Regents Of The University Of California | Vaporizer for an anesthetic having a vapor pressure about one atmosphere |
US4892109A (en) * | 1989-03-08 | 1990-01-09 | Brown & Williamson Tobacco Corporation | Simulated smoking article |
DE3908161A1 (en) | 1989-03-13 | 1990-09-27 | Bat Cigarettenfab Gmbh | Smokable article |
GB8909891D0 (en) | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
DE69034007T2 (en) | 1989-04-28 | 2003-05-08 | Riker Laboratories Inc | Inhalation device for dry powder |
WO1990013299A1 (en) | 1989-05-05 | 1990-11-15 | Northern Sydney Area Health Service | Fertility enhancement |
US4941483A (en) | 1989-09-18 | 1990-07-17 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US6313176B1 (en) | 1989-10-17 | 2001-11-06 | Everett J. Ellinwood, Jr. | Dosing method of administering deprenyl via intraoral administration or inhalation administration |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5224498A (en) | 1989-12-01 | 1993-07-06 | Philip Morris Incorporated | Electrically-powered heating element |
US5408574A (en) | 1989-12-01 | 1995-04-18 | Philip Morris Incorporated | Flat ceramic heater having discrete heating zones |
US5060671A (en) * | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5269327A (en) | 1989-12-01 | 1993-12-14 | Philip Morris Incorporated | Electrical smoking article |
US5144962A (en) | 1989-12-01 | 1992-09-08 | Philip Morris Incorporated | Flavor-delivery article |
US5093894A (en) * | 1989-12-01 | 1992-03-03 | Philip Morris Incorporated | Electrically-powered linear heating element |
US5109180A (en) | 1989-12-14 | 1992-04-28 | Phillips Petroleum Company | Apparatus providing a shatter-resistant electric lamp |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
GB2239807A (en) | 1990-01-09 | 1991-07-17 | Boc Group Plc | Anaesthetic vaporiser |
US5376386A (en) | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
US5099861A (en) * | 1990-02-27 | 1992-03-31 | R. J. Reynolds Tobacco Company | Aerosol delivery article |
US5156170A (en) | 1990-02-27 | 1992-10-20 | R. J. Reynolds Tobacco Company | Cigarette |
US5118494A (en) | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5366770A (en) | 1990-04-17 | 1994-11-22 | Xingwu Wang | Aerosol-plasma deposition of films for electronic cells |
US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
SI9111010B (en) * | 1990-06-07 | 2005-02-28 | Astrazeneca Ab | 3,5-disubstituted indole derivatives as "5-ht1-similar" receptor agonists |
US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
US5455043A (en) | 1990-06-13 | 1995-10-03 | Fischel-Ghodsian; Fariba | Device for controlled release of vaporous medications through nasal route |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
EP0469797B2 (en) * | 1990-08-02 | 2001-12-12 | Datex-Ohmeda Inc. | Anaesthetic vaporiser |
US5060667A (en) | 1990-08-16 | 1991-10-29 | Brown & Williamson Tobacco Corporation | Smoking article |
US5292499A (en) * | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5166202A (en) | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
NO904226D0 (en) | 1990-09-28 | 1990-09-28 | Forsvarets Forsknings | MOISTURE DEVICES. |
US5179966A (en) * | 1990-11-19 | 1993-01-19 | Philip Morris Incorporated | Flavor generating article |
US5095921A (en) * | 1990-11-19 | 1992-03-17 | Philip Morris Incorporated | Flavor generating article |
HU219778B (en) | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Process for producing n-acyl-2,3-benzodiazepine derivatives, their acid additional salts and pharmaceutical compositions containing them and a grop of the compounds and pharmaceutical compositions containing them |
US5519019A (en) | 1990-12-21 | 1996-05-21 | Gyogyszerkutato Intezet | N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same |
FR2671487B1 (en) | 1991-01-14 | 1993-03-19 | Oreal | USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION. |
ATE179605T1 (en) | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | ANTIREACTIVE ANTIASTHMATIC EFFECT OF ACETYL SALICYLIC ACID BY INHALATION |
US5226411A (en) | 1991-03-07 | 1993-07-13 | Walter Levine | Aerosol nebulizer heater |
US5505214A (en) * | 1991-03-11 | 1996-04-09 | Philip Morris Incorporated | Electrical smoking article and method for making same |
US5249586A (en) | 1991-03-11 | 1993-10-05 | Philip Morris Incorporated | Electrical smoking |
US5479948A (en) * | 1993-08-10 | 1996-01-02 | Philip Morris Incorporated | Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor |
US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
US5817656A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Mental disorders |
US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
US5938117A (en) | 1991-04-24 | 1999-08-17 | Aerogen, Inc. | Methods and apparatus for dispensing liquids as an atomized spray |
GB9109442D0 (en) | 1991-05-01 | 1991-06-26 | Volex Group Plc | Apparatus for emitting a chemical agent |
US5261424A (en) | 1991-05-31 | 1993-11-16 | Philip Morris Incorporated | Control device for flavor-generating article |
US5160664A (en) | 1991-05-31 | 1992-11-03 | Msp Corporation | High output monodisperse aerosol generator |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5177071A (en) * | 1991-06-17 | 1993-01-05 | Merck & Co., Inc. | 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder |
US5285798A (en) | 1991-06-28 | 1994-02-15 | R. J. Reynolds Tobacco Company | Tobacco smoking article with electrochemical heat source |
CA2069687A1 (en) * | 1991-06-28 | 1992-12-29 | Chandra Kumar Banerjee | Tobacco smoking article with electrochemical heat source |
US5457100A (en) | 1991-12-02 | 1995-10-10 | Daniel; David G. | Method for treatment of recurrent paroxysmal neuropsychiatric |
US5363842A (en) | 1991-12-20 | 1994-11-15 | Circadian, Inc. | Intelligent inhaler providing feedback to both patient and medical professional |
GB9200047D0 (en) | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
US5229120A (en) | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
DK64592D0 (en) | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | PEPTIDES FOR THERAPEUTIC TREATMENT |
US5318033A (en) | 1992-04-17 | 1994-06-07 | Hewlett-Packard Company | Method and apparatus for increasing the frame rate and resolution of a phased array imaging system |
US5584701A (en) | 1992-05-13 | 1996-12-17 | University Of Florida Research Foundation, Incorporated | Self regulating lung for simulated medical procedures |
US5391081A (en) * | 1992-05-13 | 1995-02-21 | University Of Florida Research Foundation, Incorporated | Method and apparatus for simulating neuromuscular stimulation during medical surgery |
US5525329A (en) | 1992-05-21 | 1996-06-11 | The Johns Hopkins University | Inhibition of phosphodiesterase in olfactory mucosa |
KR100208979B1 (en) | 1992-06-12 | 1999-07-15 | 야스이 쇼사꾸 | Pharmaceutical preparation for intra-airway administration |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5622944A (en) | 1992-06-12 | 1997-04-22 | Affymax Technologies N.V. | Testosterone prodrugs for improved drug delivery |
US5284133A (en) * | 1992-07-23 | 1994-02-08 | Armstrong Pharmaceuticals, Inc. | Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means |
US5322075A (en) | 1992-09-10 | 1994-06-21 | Philip Morris Incorporated | Heater for an electric flavor-generating article |
US5613505A (en) | 1992-09-11 | 1997-03-25 | Philip Morris Incorporated | Inductive heating systems for smoking articles |
US5333106A (en) | 1992-10-09 | 1994-07-26 | Circadian, Inc. | Apparatus and visual display method for training in the power use of aerosol pharmaceutical inhalers |
US5970973A (en) | 1993-01-29 | 1999-10-26 | Aradigm Corporation | Method of delivering insulin lispro |
US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5888477A (en) | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5372148A (en) | 1993-02-24 | 1994-12-13 | Philip Morris Incorporated | Method and apparatus for controlling the supply of energy to a heating load in a smoking article |
US5468936A (en) | 1993-03-23 | 1995-11-21 | Philip Morris Incorporated | Heater having a multiple-layer ceramic substrate and method of fabrication |
GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
US5497763A (en) * | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
EP0705115A1 (en) | 1993-06-03 | 1996-04-10 | von Schrader, Barthold | Inhalator |
US5666977A (en) | 1993-06-10 | 1997-09-16 | Philip Morris Incorporated | Electrical smoking article using liquid tobacco flavor medium delivery system |
BR9406968A (en) | 1993-06-29 | 1996-08-06 | Voges Innovation Pty Ltd | Dispenser |
US5388574A (en) * | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
DE4328243C1 (en) | 1993-08-19 | 1995-03-09 | Sven Mielordt | Smoke or inhalation device |
US5456247A (en) | 1993-08-26 | 1995-10-10 | Iowa State University Research Foundation, Inc. | Method for delivering drugs soluble in a vaporization vehicle |
US5462740A (en) | 1993-09-17 | 1995-10-31 | Athena Neurosciences, Inc. | Rectally-administered, epileptic-seizure-inhibiting composition |
US5400969A (en) * | 1993-09-20 | 1995-03-28 | Keene; Christopher M. | Liquid vaporizer and diffuser |
SE9303574D0 (en) | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method of manufacturing thereof |
FI98270C (en) * | 1993-11-29 | 1997-05-26 | Instrumentarium Oy | Method and apparatus for evaporation of anesthetic agent |
MA23420A1 (en) | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | BICYCLIC FIBRINOGEN ANTAGONISTS. |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
US5522008A (en) | 1994-03-16 | 1996-05-28 | Bernard; Costello J. | Device for heating and vaporizing a vaporizable module |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
MX9604393A (en) | 1994-03-30 | 1997-07-31 | Procter & Gamble | Combined skin moisturizing and cleansing bar composition. |
US6102036A (en) * | 1994-04-12 | 2000-08-15 | Smoke-Stop | Breath activated inhaler |
AU700162B2 (en) | 1994-05-13 | 1998-12-24 | Aradigm Corporation | Narcotic containing aerosol formulation |
US5457101A (en) | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
DE4425255A1 (en) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulation for inhalation application |
US5456677A (en) | 1994-08-22 | 1995-10-10 | Spector; John E. | Method for oral spray administration of caffeine |
JPH10504825A (en) | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | Bicyclic compound |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5537507A (en) | 1994-09-28 | 1996-07-16 | Advanced Ceramics Corporation | Coated flash evaporator heater |
JPH10511928A (en) | 1994-10-14 | 1998-11-17 | グラクソ、ウェルカム、ソシエタ、ペル、アツィオーニ | Use of a CCK-B receptor antagonist for the treatment of sleep disorders |
US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
ATE274341T1 (en) | 1995-02-24 | 2004-09-15 | Elan Pharma Int Ltd | AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
DE19507410C2 (en) | 1995-03-03 | 1997-05-22 | Gsf Forschungszentrum Umwelt | Method and device for producing aerosols |
US5565148A (en) | 1995-03-16 | 1996-10-15 | Minnesota Mining And Manufacturing Company | Device for selectively providing a multiplicity of aromas |
US6014970A (en) * | 1998-06-11 | 2000-01-18 | Aerogen, Inc. | Methods and apparatus for storing chemical compounds in a portable inhaler |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
HU219900B (en) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Metered dose inhaler |
US5725756A (en) | 1995-04-18 | 1998-03-10 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts with supercritical reaction media |
US5690809A (en) | 1995-04-18 | 1997-11-25 | Center For Research, Inc. | In situ mitigation of coke buildup in porous catalysts by pretreatment of hydrocarbon feed to reduce peroxides and oxygen impurities |
US5776928A (en) | 1995-04-21 | 1998-07-07 | Eli Lilly And Company | Method for treating dyskinesias with olanzapine |
FR2733594B1 (en) | 1995-04-28 | 1997-06-06 | France Etat | DEVICE FOR THE SAMPLING OF GASEOUS SUBSTANCES, LIQUIDS, AEROSOLS OR EVEN OF POWDERY MATERIALS, FOR THEIR IN SITU ANALYSIS |
US5809997A (en) | 1995-05-18 | 1998-09-22 | Medtrac Technologies, Inc. | Electronic medication chronolog device |
US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
GB9512708D0 (en) | 1995-06-22 | 1995-08-23 | Reckitt & Colman Inc | Improvements in or relating to organic compounds |
US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
US6209538B1 (en) | 1995-08-02 | 2001-04-03 | Robert A. Casper | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US5591409A (en) * | 1995-08-15 | 1997-01-07 | Watkins; Carl J. | Providing aromas |
SE9503141D0 (en) | 1995-09-12 | 1995-09-12 | Siemens Elema Ab | Anesthesia apparatus |
US5649554A (en) | 1995-10-16 | 1997-07-22 | Philip Morris Incorporated | Electrical lighter with a rotatable tobacco supply |
US6013050A (en) * | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
US5564442A (en) | 1995-11-22 | 1996-10-15 | Angus Collingwood MacDonald | Battery powered nicotine vaporizer |
US6041777A (en) | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
DK0870497T3 (en) | 1995-12-14 | 2004-05-24 | Taisho Pharmaceutical Co Ltd | aerosol |
SE9504580L (en) | 1995-12-21 | 1997-06-22 | Siemens Elema Ab | Procedure for gasification of an anesthetic fluid and a carburetor |
US5829436A (en) | 1996-02-05 | 1998-11-03 | Aradigm Corporation | Ventilation imaging using a fine particle aerosol generator |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
GB9604329D0 (en) | 1996-02-29 | 1996-05-01 | Ici Plc | Electrostatic spraying |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
WO1997033581A1 (en) | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US5944012A (en) | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
EP0906104A4 (en) | 1996-03-25 | 2003-12-10 | Lilly Co Eli | Method for treating pain |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
GB2312848B (en) | 1996-04-26 | 1999-11-17 | Bespak Plc | Controlled flow inhalers |
US5743251A (en) | 1996-05-15 | 1998-04-28 | Philip Morris Incorporated | Aerosol and a method and apparatus for generating an aerosol |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5929093A (en) | 1996-06-13 | 1999-07-27 | Mayo Foundation For Medical Education And Research | Bifunctional acetylcholinesterase reactivators |
KR100267462B1 (en) | 1996-06-17 | 2000-10-16 | 미즈노 마사루 | Flavor generating product and flavor generating tool |
US6089857A (en) | 1996-06-21 | 2000-07-18 | Japan Tobacco, Inc. | Heater for generating flavor and flavor generation appliance |
GB9613015D0 (en) | 1996-06-21 | 1996-08-28 | Reckitt & Colman Inc | Device |
US6004516A (en) | 1996-08-06 | 1999-12-21 | Illinois Institute Of Technology | Apparatus for generating odor upon electronic signal demand |
US6325475B1 (en) | 1996-09-06 | 2001-12-04 | Microfab Technologies Inc. | Devices for presenting airborne materials to the nose |
AU4807197A (en) | 1996-10-03 | 1998-04-24 | Paul Bunn | Hydrophilic microparticles and methods to prepare same |
US5934289A (en) | 1996-10-22 | 1999-08-10 | Philip Morris Incorporated | Electronic smoking system |
US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6694975B2 (en) * | 1996-11-21 | 2004-02-24 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US5878752A (en) | 1996-11-25 | 1999-03-09 | Philip Morris Incorporated | Method and apparatus for using, cleaning, and maintaining electrical heat sources and lighters useful in smoking systems and other apparatuses |
US5744469A (en) | 1996-11-26 | 1998-04-28 | Eli Lilly And Company | Method for treating dermatitis |
CA2222830C (en) | 1996-12-02 | 2004-03-30 | Fisher & Paykel Limited | Humidifier sleep apnea treatment apparatus |
DE59804534D1 (en) | 1997-02-05 | 2002-07-25 | Jago Res Ag Muttenz | MEDICAL AEROSOL FORMULATIONS |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US6051257A (en) | 1997-02-24 | 2000-04-18 | Superior Micropowders, Llc | Powder batch of pharmaceutically-active particles and methods for making same |
US5769621A (en) | 1997-05-23 | 1998-06-23 | The Regents Of The University Of California | Laser ablation based fuel ignition |
US5907075A (en) | 1997-06-11 | 1999-05-25 | The University Of Kansas | Solid acid supercritical alkylation reactions using carbon dioxide and/or other co-solvents |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5928520A (en) | 1997-07-16 | 1999-07-27 | Abanaki Corporation | Method and apparatus for extracting ground water contaiminants |
KR100289448B1 (en) | 1997-07-23 | 2001-05-02 | 미즈노 마사루 | Flavor generator |
US6090212A (en) | 1997-08-15 | 2000-07-18 | Micro C Technologies, Inc. | Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate |
US5855564A (en) * | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
US6390453B1 (en) | 1997-10-22 | 2002-05-21 | Microfab Technologies, Inc. | Method and apparatus for delivery of fragrances and vapors to the nose |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US5900249A (en) | 1998-02-09 | 1999-05-04 | Smith; David J. | Multicomponent pain relief topical medication |
US6044777A (en) | 1998-02-09 | 2000-04-04 | Walsh; Michael J. | Composite metal safe and method of making |
US6158431A (en) | 1998-02-13 | 2000-12-12 | Tsi Incorporated | Portable systems and methods for delivery of therapeutic material to the pulmonary system |
US5996589A (en) * | 1998-03-03 | 1999-12-07 | Brown & Williamson Tobacco Corporation | Aerosol-delivery smoking article |
US6544542B1 (en) | 1998-03-05 | 2003-04-08 | Nippon Shinyaku Co., Ltd. | Fat emulsions for inhalational administration |
EP1073432B1 (en) | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
US6211171B1 (en) | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
US6095153A (en) | 1998-06-19 | 2000-08-01 | Kessler; Stephen B. | Vaporization of volatile materials |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
US6509005B1 (en) | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
US6255334B1 (en) | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
DE19854007C2 (en) | 1998-11-12 | 2001-05-17 | Reemtsma H F & Ph | Inhalable aerosol delivery system |
US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
JP3506618B2 (en) | 1998-11-18 | 2004-03-15 | ウシオ電機株式会社 | Incandescent light bulb for yellow light emission |
US6376550B1 (en) | 1999-02-09 | 2002-04-23 | Asta Medica Ag | Pharmaceutical compositions containing tramadol for migraine |
US6591839B2 (en) | 1999-02-17 | 2003-07-15 | Dieter Meyer | Filter material for reducing harmful substances in tobacco smoke |
US6053176A (en) | 1999-02-23 | 2000-04-25 | Philip Morris Incorporated | Heater and method for efficiently generating an aerosol from an indexing substrate |
US6309986B1 (en) | 1999-05-07 | 2001-10-30 | S. C. Johnson & Son, Inc. | Mat for dispensing volatile materials |
US6328033B1 (en) * | 1999-06-04 | 2001-12-11 | Zohar Avrahami | Powder inhaler |
US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US6235177B1 (en) * | 1999-09-09 | 2001-05-22 | Aerogen, Inc. | Method for the construction of an aperture plate for dispensing liquid droplets |
CA2379640C (en) * | 1999-09-30 | 2006-11-28 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
DE10001035A1 (en) | 2000-01-13 | 2001-07-26 | Bayer Ag | Active ingredient chip with integrated heating element |
ATE392885T1 (en) | 2000-02-28 | 2008-05-15 | Pharmakodex Ltd | ADMINISTRATION SYSTEMS FOR ORAL MEDICATIONS |
EP1265504B1 (en) * | 2000-03-23 | 2009-07-22 | Pmpi Llc | Electrical smoking system and method |
US6632047B2 (en) | 2000-04-14 | 2003-10-14 | Board Of Regents, The University Of Texas System | Heater element for use in an in situ thermal desorption soil remediation system |
JP2001299916A (en) | 2000-04-18 | 2001-10-30 | Kao Corp | Mask-shaped inhalator |
WO2001080895A2 (en) | 2000-04-26 | 2001-11-01 | First Horizon Pharmaceutical Corporation | Methods and compositions for the treatment of cardiac indications |
MY136453A (en) * | 2000-04-27 | 2008-10-31 | Philip Morris Usa Inc | "improved method and apparatus for generating an aerosol" |
JP2004513071A (en) | 2000-05-23 | 2004-04-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Method of treating respiratory disease associated with elastic fiber injury of the lung |
FR2812545B1 (en) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS |
US6514482B1 (en) * | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
WO2002056932A2 (en) | 2000-10-27 | 2002-07-25 | Emlin Biosciences | Thermal vaporizing device for drug delivery |
US20030121906A1 (en) | 2000-11-29 | 2003-07-03 | Abbott Richard C. | Resistive heaters and uses thereof |
US6701921B2 (en) | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
US6681998B2 (en) * | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US6443152B1 (en) | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
US6680668B2 (en) * | 2001-01-19 | 2004-01-20 | Vishay Intertechnology, Inc. | Fast heat rise resistor using resistive foil |
US20020176841A1 (en) | 2001-03-19 | 2002-11-28 | Praecis Pharmaceuticals Inc. | Pharmaceutical formulations for sustained release |
SE518397C2 (en) * | 2001-04-05 | 2002-10-01 | Microdrug Ag | Method and apparatus for releasing powder and inhaler device for administering medical powder |
US20030004142A1 (en) * | 2001-04-18 | 2003-01-02 | Prior Christopher P. | Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20030138508A1 (en) | 2001-12-18 | 2003-07-24 | Novack Gary D. | Method for administering an analgesic |
US20030118512A1 (en) | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US7585493B2 (en) * | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
US20030051728A1 (en) * | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7645442B2 (en) * | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
NZ529417A (en) | 2001-05-24 | 2006-11-30 | Alexza Pharmaceuticals Inc | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
WO2002094244A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
PT1412829E (en) * | 2001-07-31 | 2014-07-10 | Philip Morris Products S A S | Method and apparatus for generating a volatilized liquid |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US6568390B2 (en) | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US6648950B2 (en) | 2001-10-15 | 2003-11-18 | Hewlett-Packard Development Company, L.P. | Electro-thermal odor-releasing inks and methods for releasing odors from the same |
US6779520B2 (en) | 2001-10-30 | 2004-08-24 | Iep Pharmaceutical Devices Inc. | Breath actuated dry powder inhaler |
WO2003041693A1 (en) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
AU2002364508A1 (en) | 2001-11-21 | 2003-06-10 | Alexza Molecular Delivery Corporation | Open-celled substrates for drug delivery |
WO2003057188A1 (en) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
US6684880B2 (en) * | 2001-12-04 | 2004-02-03 | Hewlett-Packard Development Company, L.P. | Applicator for dispensing bioactive compositions and methods for using the same |
US20030106551A1 (en) | 2001-12-06 | 2003-06-12 | Sprinkel F. Murphy | Resistive heater formed inside a fluid passage of a fluid vaporizing device |
US6681769B2 (en) * | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
CN1176075C (en) | 2001-12-07 | 2004-11-17 | 北京燕山石油化工公司研究院 | Pyrrole derivative preparation method |
US6701922B2 (en) | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
US6772756B2 (en) | 2002-02-09 | 2004-08-10 | Advanced Inhalation Revolutions Inc. | Method and system for vaporization of a substance |
US6961515B2 (en) | 2002-02-15 | 2005-11-01 | Dekko Technologies, Inc. | PTC heater with flexible printed circuit board |
US6728478B2 (en) | 2002-02-21 | 2004-04-27 | Dekko Heating Technologies, Inc. | Heated chemical delivery system |
AU2003239433A1 (en) * | 2002-05-13 | 2003-11-11 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
WO2003103387A2 (en) * | 2002-06-06 | 2003-12-18 | S.C. Johnson & Son, Inc. | Localized surface volatilization |
CA2497845C (en) | 2002-09-06 | 2012-08-14 | Chrysalis Technologies Incorporated | Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
US6772757B2 (en) | 2002-10-25 | 2004-08-10 | Chrysalis Technologies Incorporated | Concentric controlled temperature profile fluid vaporizing device |
AU2003295823B2 (en) | 2002-11-26 | 2009-11-05 | Alexza Pharmaceuticals, Inc. | Treatment of headache with antipsychotics delivered by inhalation |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
MXPA05005611A (en) | 2002-11-26 | 2005-07-27 | Alexza Pharmaceuticals Inc | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain. |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US20050037506A1 (en) * | 2003-08-04 | 2005-02-17 | Alexza Molecular Delivery Corporation | Methods of determining film thicknesses for an aerosol delivery article |
CA2534566A1 (en) * | 2003-08-04 | 2005-02-24 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing and use |
JP2007526796A (en) | 2003-12-15 | 2007-09-20 | アレックザ ファーマシューティカルズ, インコーポレイテッド | Treatment of breakthrough pain by drug aerosol inhalation |
WO2005059804A2 (en) | 2003-12-16 | 2005-06-30 | Alexza Pharmaceuticals, Inc. | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US20060032496A1 (en) * | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
EP2246086A3 (en) * | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
EP1809240A4 (en) | 2004-10-12 | 2010-06-16 | Alexza Pharmaceuticals Inc | Cardiac safe, rapid medication delivery |
WO2008080170A1 (en) | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
ES2594867T3 (en) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20080306285A1 (en) | 2007-04-27 | 2008-12-11 | Alexza Pharmaceuticals, Inc. | Heat-Labile Prodrugs |
-
2004
- 2004-06-03 US US10/861,554 patent/US7540286B2/en active Active
-
2009
- 2009-05-29 US US12/474,680 patent/US8333197B2/en active Active
-
2011
- 2011-04-01 US US13/078,654 patent/US20110233043A1/en not_active Abandoned
-
2012
- 2012-12-17 US US13/717,630 patent/US20130180525A1/en not_active Abandoned
-
2016
- 2016-12-22 US US15/388,881 patent/US20170105246A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5586550A (en) * | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US6554201B2 (en) * | 2001-05-02 | 2003-04-29 | Aerogen, Inc. | Insert molded aerosol generator and methods |
US8387612B2 (en) * | 2003-05-21 | 2013-03-05 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US20050051165A1 (en) * | 2003-09-04 | 2005-03-10 | Cole Maury D. | Substance inhalation system |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11065400B2 (en) | 2001-06-05 | 2021-07-20 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US10786635B2 (en) | 2010-08-26 | 2020-09-29 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US11484668B2 (en) | 2010-08-26 | 2022-11-01 | Alexza Pharmauceticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US11839714B2 (en) | 2010-08-26 | 2023-12-12 | Alexza Pharmaceuticals, Inc. | Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter |
US10166224B2 (en) | 2013-07-11 | 2019-01-01 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US11458130B2 (en) | 2013-07-11 | 2022-10-04 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid and applications therein |
US11511054B2 (en) | 2015-03-11 | 2022-11-29 | Alexza Pharmaceuticals, Inc. | Use of antistatic materials in the airway for thermal aerosol condensation process |
US11241383B2 (en) | 2016-12-09 | 2022-02-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
US11717479B2 (en) | 2016-12-09 | 2023-08-08 | Alexza Pharmaceuticals, Inc. | Method of treating epilepsy |
WO2021105476A1 (en) * | 2019-11-29 | 2021-06-03 | Nicoventures Trading Limited | Non-combustible aerosol provision device |
Also Published As
Publication number | Publication date |
---|---|
US8333197B2 (en) | 2012-12-18 |
US20050268911A1 (en) | 2005-12-08 |
US20130180525A1 (en) | 2013-07-18 |
US20110233043A1 (en) | 2011-09-29 |
US20090235926A1 (en) | 2009-09-24 |
US7540286B2 (en) | 2009-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170105246A1 (en) | Multiple Dose Condensation Aerosol Devices and Methods of Forming Condensation Aerosols | |
CA2567840C (en) | Multiple dose condensation aerosol devices and methods of forming condensation aerosols | |
US20210106775A1 (en) | Electrical condensation aerosol device | |
US6223744B1 (en) | Wearable aerosol delivery apparatus | |
US6951215B1 (en) | Drug delivery device for animals | |
US8534277B2 (en) | Device, system and method for targeting aerosolized particles to a specific area of the lungs | |
EP4223335A2 (en) | Dry powder delivery device and methods of use | |
US7493898B2 (en) | Inhalation apparatus | |
US20070062526A1 (en) | Temperature controlling device for aerosol drug delivery | |
WO1994009842A1 (en) | Method and devices for delivering drugs by inhalation | |
JP2002504833A (en) | Device for administering insulin at a controlled dose by controlling the total inhalation volume | |
US20040065324A1 (en) | Thermal inhaler | |
EP3941556B1 (en) | Aerosol delivery system | |
EP3711592A1 (en) | Aerosol delivery system | |
WO2020187941A1 (en) | Aerosol delivery system | |
EP3711603A1 (en) | Aerosol delivery system | |
EP3711799A1 (en) | Aerosol delivery system | |
EP3711593A1 (en) | Aerosol delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALEXZA PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CROSS, STEVEN D.;HERBETTE, MATTHIEU;KELLY, ANDREW J.G.;AND OTHERS;REEL/FRAME:040878/0012 Effective date: 20040528 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION COUNTED, NOT YET MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |